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Parkinson’s disease (PD) is characterized by loss of dopamine neurons in the substan-
tia nigra of the brain. Since there are limited treatment options for PD, neuroprotective
agents are currently being tested as a means to slow disease progression. Agents tar-
geting oxidative stress, mitochondrial dysfunction, and inﬂammation are prime candidates
for neuroprotection. This review identiﬁes Rasagiline, Minocycline, and creatine, as the
most promising neuroprotective agents for PD, and they are all currently in phase III tri-
als. Other agents possessing protective characteristics in delaying PD include stimulants,
vitamins, supplements, and other drugs. Additionally, combination therapies also show
beneﬁts in slowing PD progression. The identiﬁcation of neuroprotective agents for PD
provides us with therapeutic opportunities for modifying the course of disease progression
and, perhaps, reducing the risk of onset when preclinical biomarkers become available.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder that
resultsfromthedeathofneuronalcellscontainingdopamine(DA)
inthemidbrain.Usuallyatthetimeofclinicaldiagnosisthepatient
hasalreadylost60%ormoreoftheneuronsinthesubstantianigra
pars compacta (SNpc). PD affects approximately 3% of the pop-
ulation over the age of 65. Most cases of PD are idiopathic and
current evidence suggests that environmental factors along with
a genetic susceptibility are the major causes (Lang and Lozano,
1998). Genetic forms of PD exist, but they represent less than 5%
of thecases(Langston,1998).Oxidativestress,mitochondrialdys-
function, and inﬂammation play key roles in the development of
PD (Michel et al., 2002; Jenner, 2003). Because a large propor-
tion of the baby boomers are reaching the typical age of onset for
PD,therehavebeenincreasedeffortstosearchforneuroprotective
agents that will prevent the irreversible loss of neurons. In this
review we summarize the current evidence that neuroprotective
agents may be useful for preventing or slowing the development
of PD.
CAFFEINE AND NICOTINE ARE PROMISING
NEUROPROTECTIVE STIMULANTS FOR PARKINSON’S
DISEASE
Mostepidemiologicalstudiessupportaprotectivebeneﬁtofdrink-
ing caffeinated beverages (Ross et al., 2000; Ascherio et al., 2001;
Saaksjarvi et al., 2008), although one study showed no beneﬁt
(Xu et al., 2006). Animal studies in general also indicate that caf-
feine is neuroprotective. Chronic caffeine administration in mice
provided protection against dopaminergic neuron toxicity from
exposure to a combination of paraquat and maneb (van den
Pol, 1986; Kachroo et al., 2010). In addition, acute and chronic
treatment of mice with caffeine reduced the effect of acute 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)(Chenetal.,
2001) and 6-hydroxydopamine (6-OHDA) treatment on striatal
DA loss (Joghataie et al., 2004). Motor dysfunctions were atten-
uated and DA levels increased after caffeine treatment in MPTP-
and 6-OHDA-treated animals (Joghataie et al.,2004;Aguiar et al.,
2006).Inaddition,caffeinetreatmentpartiallyrestorednoradren-
aline, DA, 3,4 dihydroxyphenylacetic acid, homovanillic acid, and
their metabolites in 6-OHDA-lesioned rats (Aguiar et al., 2006).
Although serotonin levels decreased, levels of its metabolite, 5-
hydroxyindoleacetic acid,were unchanged. In treatment,the time
frame of caffeine’s beneﬁcial effects is extended by its metabolites
theophylline and paraxanthine,which also exert protective effects
(Xu et al.,2010).An additional beneﬁt of caffeine is that tolerance
does not develop with long-term exposure (Xu et al.,2002).
The effect of estrogen on caffeine’s neuroprotective capabil-
ities is signiﬁcant. Results from epidemiological studies showed
improvement in male Parkinson’s patients only (Ascherio et al.,
2001;Costaetal.,2010).Interestingly,inpost-menopausalwomen,
caffeine consumption is also linked to a reduced risk of PD, but
only among those who were not taking hormone-replacement
therapy(Ascherioetal.,2003).Inafollowupcase-controlledstudy
the relationships between gender, caffeine intake, estrogen, and
the risk of PD were examined by investigating single nucleotide
polymorphisms (SNPs) in the caffeine metabolizing genes [the
cytochrome P450 (CYP) gene CYP1A2 and N-acetyltransferase
2 (NAT2)] and estrogen receptors (ESR1 and ESR2). A signif-
icant increased risk of PD was observed in women who had the
CYP1A2polymorphism,whereasNAT2,ESR1,andESR2hadmar-
ginal effects on PD risk (Palacios et al., 2010). In another study,
estrogen and caffeine were administered to both male and female
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MPTP-treated mice, which prevented neuroprotection in all of
the animals (Xu et al., 2006). Thus, the beneﬁcial effects of caf-
feine may be limited to men and post-menopausal women who
are not receiving hormone-replacement therapy.
Complimentarygeneticandpharmacologicaldatafromrodent
studies indicate that one mechanism by which caffeine reduces
dopaminergic toxicity is through antagonism of adenosine A2A
receptors (see review Prediger, 2010). In contrast, the indirect
pathway of the basal ganglia contributes to the progression of
PD via glutamatergic neuron overstimulation through adenosine
A2A receptors(Boveetal.,2005b).CaffeinealsoactivatesPI3K/Akt
signaling and thus reduces apoptosis (Nakaso et al.,2008).
Nicotine is comparable to caffeine with regards to lowering
the risk of developing PD (Simon et al., 2009). In a Chinese epi-
demiological study, there was a signiﬁcant reduced rate of PD in
individuals who drank coffee and smoked cigarettes, which was
dose-dependent (Tan et al., 2003). Toxicant responsive enzymes,
including CYP1A1,CYP2E1,and glutathione S-transferase (GST)
enzymes GST-ya, GST-yc, GSTA4-4, and vesicular monoamine
transporter-2playcriticalrolesinmodulatingtheprotectiveeffects
of nicotine and caffeine in MPTP-treated animals (Singh et al.,
2008).Interestingly,decaffeinatedcoffeeandnicotine-freetobacco
were neuroprotective in a Drosophila model of PD, but, the neu-
roprotection depended on the cytoprotective transcription factor
nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) and cafestol
(an activator) (Trinh et al., 2010). This suggests that coffee and
tobacco containing Nrf2-activating compounds account for the
decreased risk of PD.
Nicotine without caffeine, has also shown beneﬁcial effects in
reducing the risk of PD in epidemiological studies and animal
studies (reviewed in Quick, 2004). Animals receiving nicotine at
low doses (0.1mg/kg s.c) in vitro showed reduce DA depletion
resultingfromMPTPand6-OHDAtreatments(Fergeretal.,1998;
Costa et al., 2001). A large dosage of nicotine (0.4mg/kg s.c),
however, enhanced dopamine loss in vivo (Ferger et al., 1998).
Additionally, nicotine attenuated motor deﬁcits and nigrostri-
atal neurodegeneration produced by chronic administration of
rotenone in mice. In 6-OHDA-lesioned rats, subchronic nicotine
(0.4mg/kg) and apomorphine treatment reduced parkinsonian
contralateral rotations (Meshul et al., 2002). Chronic nicotine
treatment in MPTP-treated primates restored and maintained
dopaminergic function and prevented cell loss in the SNpc (Quik
et al., 2006). In addition, simple exposure to tobacco smoke prior
to MPTP treatment reduced the loss of striatal DA in mice (Carr
and Rowell, 1990). Additionally, in humans, acute nicotine treat-
ment can improve impaired controlled semantic processing in PD
patients (Holmes et al., 2011). To date, nicotine is still in Phase II
trials focusing on optimizing dosage and increasing sample size.
Nicotine is an alkaloid that is the predominant ingredient
found in cigarettes. It has a high rate of absorption and diffuses
quickly through the bloodstream and across the blood–brain bar-
rier (BBB). Nicotine reduces the oxidative stress that is associated
withtheprogressionofPDbyscavengingfreeradicalsproducedby
monoamine oxidase-B (MAO-B), which metabolizes DA (Fowler
etal.,1996;Iidaetal.,1999).Inaddition,nicotineiscapableofaug-
menting neurotrophic factors and cholinergic receptor expression
(Ferrea and Winterer, 2009). Nicotine pretreatment attenuated
the loss of dopaminergic cells in MPTP-induced mesencephalic
neurons (Quik and Jeyarasasingam, 2000). Neuroprotection was
blocked by a nicotine receptor antagonist suggesting the effect
was mediated by nicotinic acetylcholine receptors (nAChR; Quik
and Jeyarasasingam, 2000). These results suggest that the neuro-
protective mechanism of nicotine may be directly or indirectly
connected to the nAChR up-regulation in cerebral cortical blood
ﬂow (Linville et al.,1993). Moreover,it indicates that nAChR ago-
nists could be beneﬁcial in slowing the progression of PD (Mag-
gio et al., 1997). Recently it has been suggested that stimulating
nAChRs or PI3KAkt/PKB signaling could suppress dopaminergic
cell death induced by rotenone (Takeuchi et al., 2009). In similar
studies, nicotine induced ﬁbroblast growth factor (FGF-2) and
the brain-derived neurotrophic factor (BDNF) in the striatum
(Maggio et al., 1997). Neuroprotection of DA neurons by nico-
tine is primarily gated by cytoplasmic Ca2+ through a mechanism
involving α-bungarotoxin-sensitive (α7) nAChRs and secondarily
through T-type voltage-gated calcium channels (Toulorge et al.,
2011).
URATE AND URIC ACID HAVE MODERATE
NEUROPROTECTIVE PROPERTIES
Uric acid (UA) is a natural antioxidant that can reduce oxidative
stressbyactingasascavengerof freeradicalsandanironchealator
(Ames et al., 1981; Davies et al., 1986; Yu et al., 1998; Hink et al.,
2002). Urate suppresses oxyradical accumulation (Yu et al.,1998),
inhibits cytotoxic activity of lactoperoxidase (Everse and Coates,
2004), and protects against DA-induced apoptosis (Jones et al.,
2000). UA has been found to suppress oxidative stress and prevent
dopaminergic cell death in animals (Duan et al., 2002). In addi-
tion,slowerratesofclinicalprogressionwereobservedinuntreated
early stage PD patients who have higher plasma, serum, and cere-
brospinal ﬂuid (CSF) concentrations of UA (Schwarzschild et al.,
2008; Ascherio et al., 2009). In contrast, lower levels of urate were
presentinCSF(Tohgietal.,1993)andpost-mortemintheSNpcof
patientswithPD(ChurchandWard,1994).Inapopulation-based
cohort study of 4,695 participants aged 55years and older, higher
serum levels of UA were associated with a signiﬁcantly decreased
risk of PD (de Lau et al., 2005). Urate therapy reduced the risk
of PD in a dose-dependent manner (de Lau et al., 2005; Schwarz-
schild et al., 2008). Additionally in a prospective study of subjects
with early stage PD there was a 49% reduction in the progression
of the disease with high urate intake (Schwarzschild et al.,2008).
Like caffeine, urate (Alonso et al., 2007) and UA (Alonso et al.,
2007; Schwarzschild et al., 2008; Andreadou et al., 2009) show a
gender-speciﬁc bias with a greater beneﬁt observed in male PD
patients. Epidemiological studies however contradict these results
and show no gender speciﬁcity (de Lau et al., 2005; Annanmaki
et al.,2007; Chen et al., 2009).
Life style choices play an important role in PD progres-
sion. Exercise, for example, decreases PD, possibly by increasing
serum UA levels and decreasing excretion of UA (Schlesinger and
Schlesinger, 2008). Additionally, individuals who eat diets that
increase plasma urate levels have a reduced risk of PD. Dietary
changes expected to increase plasma urate levels like dairy pro-
tein (but not milk) (Choi et al.,2005) and vitamin C contribute to
reducingtheriskofPDinmen(Gaoetal.,2008).Thesestudiesalso
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suggestthataPDpatient’sdietshouldincludeadequatesourcesof
purines,suchasmeatandseafood,whichresultsinhigherconcen-
trations of UA (Annanmaki et al.,2007). Diets that result in lower
UA levels could accelerate disease progression (Annanmaki et al.,
2007). One must keep in mind however that a high concentration
of UA in the blood serum increases the risk of gout and high alco-
hol and fructose consumption compounds this risk (Choi et al.,
2004). Therefore, even if PD patients choose to modify their diet
for potential neuroprotective effects, the physician must carefully
monitor them for other at risk chronic diseases (Gao et al.,2008).
VITAMIN D, BETA-CAROTENE AND RIBOFLAVIN ARE
CANDIDATES FOR NEUROPROTECTIVE AGENTS
Vitamin E (α-tocopherol) is a lipid-soluble antioxidant that can
inhibit iron accumulation, suppress microglial activation, scav-
engeoxygenradicals,andprohibitstheperoxidationof membrane
lipids (Tappel, 1962; Burton et al., 1983; Cheeseman et al., 1988;
Chow, 1991; Lan and Jiang, 1997; Li et al., 2001). Vitamin E also
induces interleukin-1α and tumor necrosis factor (TNF)-α and
suppresses p38 MAPK and NFκB activation (Li et al., 2001). Vit-
amin E is regulated by α-tocopherol transfer protein (TTP) in
the liver and brain (Kaempf-Rotzoll et al., 2003). Studies have
demonstrated that lack of TTP causes a systemic deﬁciency of vit-
amin E in humans and mice (Traber and Sies, 1996; Yokota et al.,
2001), which can lead to enhanced oxidative stress in the brain
(Yokota et al.,2001). However,vitamin E is also believed to reduce
oxidative stress caused by iron accumulation in the brain (Lan
and Jiang, 1997). Vitamin E deﬁciency increases MPTP toxicity
in mice (Odunze et al., 1990). Vitamin E supplementation, how-
e v e r ,h a dap r o t e c t i v ee f f e c to nD An e u r o n si nt h eS N p c( Roghani
and Behzadi, 2001) and reduced DA loss (Lan and Jiang, 1997).
Pretreatment with vitamin E was shown to reduce lipid peroxi-
dation levels (Lan and Jiang, 1997), but depletion of striatal DA
was not attenuated by pretreatment (Gong et al., 1991; Chi et al.,
1992). Other studies have shown that vitamin E has no protec-
tive effects against DA-induced toxicity in PC12 cells (Offen et al.,
1996) and only partial protection in MPTP-treated rodents (Perry
et al., 1987). In addition, a genetic vitamin E deﬁciency did not
affect MPTP susceptibility in mice (Ren et al.,2006). So either the
protective effects of vitamin E is dependent on the mechanism by
whichPDisinducedorhighacutedoseof vitaminEhavedifferent
neuroprotective effects than chronic low doses (Fariss and Zhang,
2003; Ricciarelli et al.,2007).
Therearenodifferencesintheamountof vitaminEinthecere-
bellum (Dexter et al., 1992) or CSF (Molina et al., 1997) between
PD patients and healthy individuals. Clinical trials also show no
neuroprotectivebeneﬁtoftakingvitaminE(Fernandez-Calleetal.,
1992; LeWitt,1994; Morens et al.,1996).A meta-analysis however
showed a protective effect of both moderate intake (0.67–0.98)
and high intake (0.78, 0.57–1.06) of vitamin E (Etminan et al.,
2005). Thus, choosing foods that are vitamin E-rich may be neu-
roprotective (Perlmutter,1988;Zhang et al.,2002). The risk of PD
was signiﬁcantly lower in men than in women with high intake of
vitamin E from food (Zhang et al.,2002).
Vitamin C or ascorbate, is highly concentrated in the CNS,
and is associated primarily with the activity of glutamatergic neu-
rons, which makes it a good candidate for a neuroprotector or
a neuromodulator (Grunewald, 1993). Vitamin C is decreased in
vascular parkinsonisms (Paraskevas et al., 2003). Results from a
pilot study in which high doses of vitamin E and C were given to
participants showed a decrease in PD progression in early stage
patients(Fahn,1992).Yet,other studies have shown few beneﬁcial
effects of vitamin C alone and some have shown an increase risk
of PD (Scheider et al., 1997; Zhang et al., 2002; Etminan et al.,
2005). In a case-controlled study of people who consumed diets
richinvitaminC,therewasa40%riskreductionof PDthanthose
consumingsmallamounts(Perlmutter,1988).Becauseof thecon-
ﬂictingdata,thereiscurrentlynotenoughdatatosupportvitamin
C as neuroprotective for PD.
Calcitriols are a group of fat-soluble secosteroids that include
vitamin D and its derivatives D2,D 3,D 4, and D5 (Garcion et al.,
2002). D3 is obtained through the skin during sun exposure and
can be ingested (Eyles et al.,2003).Vitamin D deﬁciency is preva-
lent in PD patients (Sato et al.,1997).Vitamin D receptors (DVR)
in the brain are found primarily in dopaminergic neurons in the
SNpc (Eyles et al.,2005) andVDR mRNA expression in the blood
is a useful risk marker for identifying PD patients (Scherzer et al.,
2007).VitaminDhasanti-inﬂammatoryproperties,itcanregulate
expression of glial cell line-derived neurotrophic factor (GDNF),
andregulatescalcium(Ca2+)homeostasis(Evans,1988;Naveilhan
etal.,1996;Garcionetal.,2002;Smithetal.,2006;Chanetal.,2009;
Butler et al., 2011). A disruption of Ca2+ homeostasis accelerates
SNpc dopaminergic neuron loss (Butler et al., 2011). In contrast,
GDNFstimulationcanalleviatePDsymptomsinbothprimateand
PD patients (Gash et al., 1996; Kordower et al., 2000; Gill et al.,
2003). Vitamin D was also shown to be beneﬁcial in 6-OHDA-
treatedanimalsandincellcultures(Wangetal.,2001;Smithetal.,
2006). In addition, vitamin D increased neuromuscular function
in parkinsonian rodents (Holick, 2007). In contrast to these ﬁnd-
ings, one case-controlled human study found an increased risk of
PD with high consumption of vitamin D (Anderson et al., 1999).
Together these ﬁndings suggest that dietary intake of vitamin D
in moderate amounts may be effective in protecting individuals
fromPDprogressionalthoughfurtherstudiesareneeded(Holick,
2007).
Serum levels of vitaminA are similar between,PD patients and
controlssuggestingthatlevelsofvitaminAareunrelatedtotherisk
of PD (Fernandez-Calle et al., 1992, 1993; Jimenez-Jimenez et al.,
1993; Etminan et al., 2005). An epidemiological study, however,
found that there was a decrease in the risk of PD in individuals
who consumed foods containing carotenoids and beta-carotene
(Perlmutter,1988).VitaminA’sprecursorbeta-carotene,mayoffer
neuroprotective effects by preventing lipid peroxidation (Glover,
1960; Kartha and Krishnamurthy, 1977). A recent study showed
that pretreatment with beta-carotene partially protected against
MPTP-inducedneurotoxicityinmice(Perryetal.,1985;Yongetal.,
1986), although the same was not true of primates (Perry et al.,
1987).
Riboﬂavin,vitaminB-2,isawater-solublevitaminpresentpre-
dominatelyindairyproducts(Powers,2003).Itsbiologicallyactive
forms are ﬂavin adenine dinucleotide and ﬂavin mononucleotide,
whichareelectroncarriersthatparticipateinawiderangeofredox
reactions(Huennekens,1956;Merrilletal.,1981).Riboﬂavinplays
an active role in energy production and affects iron accumula-
tion (Sirivech et al., 1977; Powers et al., 1983; Powers, 1987). The
mechanism of action of riboﬂavin in the brain remains unknown,
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but may involve glutathione depletion,cumulative mitochondrial
DNA mutations,disturbed mitochondrial protein complexes,and
abnormal iron metabolism (Di Monte, 1991; Jenner et al., 1992;
Logroscino et al., 1997). Riboﬂavin may also effect glutathione
production (Perlmutter,1988). The amount of riboﬂavin is lower
in PD patients compared to healthy and disease controls,suggest-
ingthattakingriboﬂavinsupplementsmaybebeneﬁcial(Coimbra
and Junqueira, 2003). Intake of riboﬂavin, compared to other B-
vitamins was shown to reduce the risk of PD (Murakami et al.,
2010).Infact,theriskof PDwasreduced51%byusersobtaininga
highconsumption(Perlmutter,1988)anddailydosesofriboﬂavin
for 6months showed improved motor capacity of PD patients in
3months(CoimbraandJunqueira,2003).Thesepromisingresults
indicate that additional longitudinal studies are needed to deter-
minethelong-termeffectsof chronicadministrationof riboﬂavin
supplements.
AMONG THE SUPPLEMENTS CREATINE SHOWS THE MOST
PROMISE AS A NEUROPROTECTIVE AGENT
Coenzyme Q10 (CoQ10),also known as ubiquinone,is a promis-
ing agent for neuroprotection in PD and other neurodegenerative
diseases because of its role in the mitochondrial electron trans-
port chain (METC) and as an antioxidant (Beal and Shults,2003).
CoQ10 serves as an electron acceptor in complex I and II of the
METC. CoQ10 is protective by inhibiting SIN-1-induced apop-
tosis (Sharma et al., 2004), suppressing intra-mitochondrial and
intra-nuclear biosynthesis of 8-OH-2dG, inhibiting translocation
of caspase-3, attenuating α-synuclein expression, and blocking
intra-mitochondrial accumulation of metal ions (Ebadi et al.,
2004).
Animal studies have shown that rotenone-induced parkinson-
ism reduced CoQ10 concentrations in plasma and the striatum
with a corresponding decrease in striatal levels of DA, mitochon-
drial complex I activity and ATP levels, as well as signiﬁcant
increase in B-cell lymphoma 2 (Bcl-2) expression (Abdin and
Hamouda,2008).Administration of CoQ10 protected the nigros-
triatal dopaminergic neurons in MPTP-treated mice (Shults et al.,
1999). In addition, a diet containing CoQ10 (1,600mg/kg/day,
2months) or CoQ10 supplementation diminished neural tissue
damage (Cleren et al., 2008). CoQ10 was also effective in pre-
venting DA depletion, loss of tyrosine hydroxylase neurons and
formation of α-synuclein inclusions in the SNpc in mice (Cleren
et al.,2008).
ReducedlevelsofCoQ10arepresentinPDpatients’plasmaand
platelets (Matsubara et al., 1991; Gotz et al., 2000) and in cortex
(Hargreaves et al., 2008), which correlated with reduced activity
of complex I and II/III (Shults et al., 1997, 1999). In addition, the
percent of CoQ10 in its oxidized form is elevated in PD patients
(Sohmiya et al., 2004). Chronic administration of CoQ10 in PD
patients delays the progression of PD (Shults et al., 2002; Shults,
2003) with no adverse effects (Galpern and Cudkowicz, 2007).
Additionally, CoQ10 supplements showed promising results in
a small group of de novo PD patients during phase II clinical
trials although no follow up study has been published (Shults
et al., 2002). More recently, another human trial found inconclu-
sive results from CoQ10 supplements in PD patients (Investiga-
tors, 2007). CoQ10 (2,400mg/day) and vitamin E (1,200IU/day)
together initially was thought to be beneﬁcial for PD patients
(Shults et al., 2004), however, in Phase III trials it was deemed
futile (NINDS1).
Creatine is a guanidino compound found primarily in meat
products and is produced endogenously by the liver, kidney,
and pancreas (Tarnopolsky and Beal, 2001; Adhihetty and Beal,
2008). Creatine possesses antioxidant properties and can regulate
intracellular calcium, suppress extracellular glutamate levels, and
inhibit the opening of the mitochondrial permeability transition
pore(MPT;Figure1)(Xuetal.,1996;Lawleretal.,2002;Dedeoglu
et al.,2003).
AcombinationofCoQ10andcreatineshowsanadditiveneuro-
protective effect in chronic MPTP-treated mice (Yang et al.,2009).
Additionally,creatinehasshownpromisingneuroprotectiveeffects
in combination with CoQ10 in PD patients (Yang et al., 2009).
Alone, creatine protects against MPTP-induced DA depletion in
the SNpc (Matthews et al., 1999). Interestingly, in a stage II clini-
cal trial creatine showed a delay in the progression of PD by 50%
comparedtocontrolsthatreceivedaplacebo(Investigators,2006).
In a follow up study 18months later, creatine continued to show
efﬁcacy as a neuroprotective agent (Investigators, 2008) and it is
currently in Phase III trials (NET-PDLS2).
1http://www.ninds.nih.gov/disorders/clinical_trials/CoQ10-Trial-Update.htm
2http://clinicaltrials.gov/ct2/show/NCT00449865
FIGURE 1 |The mechanisms of action of neuroprotective agents that
are in clinical trials. Rasagiline shows neuroprotective properties by
suppressing mitochondrial apoptosis stopping the mitochondrial
permeability transition pore (MPT) opening by inhibiting caspase-3, nuclear
poly [ADP-ribose] polymerase 1 (PARP-1) activation, stopping the
translocation of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and
halting nucleosomal DNA fragmentation. Rasagiline increases the
expression of the anti-apoptotic proteins B-cell lymphoma 2 (Bcl-2) and
B-cell lymphoma-extra large (Bcl-xL) through the protein kinase C (PKC)
pathway, in addition to down-regulating the pro-apoptotic Bcl-2-associated
death promoter (Bad) and Bcl-2-associated X protein (Bax). Minocycline
inhibits the inﬂammatory response to prevent cell death and it chealates
metals. Creatine inhibits activation of the MPT and represses iron (Fe
2+)
accumulation.
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Omega-3 polyunsaturated fatty acids appear to be neuropro-
tective for several diseases (Bousquet et al., 2011) including a
small study with PD patients (da Silva et al., 2008). Animal
studies have shown that the omega-3 fatty acid docosahexaenoic
acid (DHA) can replace the omega-6 fatty acids already present
in the brains of mice that had been given supplements after
MPTP treatment (Bousquet et al., 2008). DHA is an essential
factor in growth and development in the brain (Horrocks and
Yeo, 1999) and has anti-inﬂammatory capabilities due to its abil-
ity to inhibit cyclo-oxygenase-2 (COX-2) (Massaro et al., 2006).
DHA (5–50μg/ml) protected neurons against cytotoxicity,inhib-
ited both nitrogen oxide (NO) production and Ca2+ inﬂux, and
increasedtheactivitiesof antioxidantenzymesof glutathioneper-
oxidase and glutathione reductase (Wang et al., 2003) in cell cul-
tures. DHA does not alter the levels of glutathione (GSH) (Wang
et al., 2003). Animal studies showed that DHA decreased apop-
tosis of dopaminergic cells after MPTP treatment (Ozsoy et al.,
2011). Short-term administration of DHA (100mg/kg) reduced
40% of the levodopa-induced dyskinesias in Parkinsonian pri-
mates(Samadietal.,2006).DHAalsopreservedDAlevels,tyrosine
hydroxylase (TH)-positive neurons and nuclear receptor related-
1 protein expression from MPTP-induced neurotoxicity in mice
(Bousquet et al., 2008). Chronic administration of uridine and
DHA increased the levels of neural phosphatides and proteins in
synaptic membranes (Wurtman et al., 2006) and dendritic spines
in rodents (Sakamoto et al., 2007). DHA and uridine administra-
tion also reduced parkinsonian related behaviors and elevated DA
levelsin6-OHDArats(Cansevetal.,2008).Humanstudiesonthe
effects of DHA are now needed before recommendations may be
made to PD patients.
DHA’s proposed mechanisms of neuroprotection are linked to
its anti-oxidative activity in vivo (Hashimoto et al., 2002; Yavin
et al., 2002; Calon et al., 2004; Wu et al., 2004; Bazan, 2005), its
abilitytoincreaseglutathionereductaseactivity(Hashimotoetal.,
2002) and decrease the accumulation of oxidized proteins (Calon
etal.,2004;Wuetal.,2004)andlevelsoflipidperoxideandreactive
oxygen species (ROS) (Hashimoto et al., 2002, 2005). DHA also
triggeredinactivationof cell-signalingpathwaysleadingtocaspase
activation (Calon et al.,2004,2005) and hyperphosphorylation of
tau (Green et al., 2007). In addition, DHA regulates the PI3K/Akt
cascade (Akbar and Kim, 2002; Akbar et al., 2005; Kim, 2007).
DHA has no association with beta-secretase or gamma-secretase
complex,butitcandown-regulatepresenilin-1invitro andinvivo
(Lim et al.,2005; Green et al.,2007). Other potential mechanisms
of action of DHA include regulation of inﬂammation, gene tran-
scription, and cell membrane properties (de Urquiza et al., 2000;
Salem et al., 2001; Jump, 2002).
Melatonin has been associated with nigrostriatal protection,
reducedauto-oxidationof l-3,4-dihydroxyphenylalanine,andhas
antioxidant properties (Fertl et al.,1993; Miller et al.,1996; Reiter
et al., 1997; Khaldy et al., 2000; Rocchitta et al., 2006). Decreased
levels of melatonin are present in PD patients compared to con-
trols (Sandyk, 1990). Melatonin’s free radical scavenging prop-
erties and its ability to easily pass the BBB suggest that it may be
neuroprotective(Antolinetal.,2002;seereviewMayoetal.,2005).
Animal studies have shown that melatonin can prevent cell
death and damage induced by MPTP (Acuna-Castroviejo et al.,
1997),6-OHDA(Kimetal.,1998),andiron(Maharajetal.,2006a)
inneuronsandastrocytes(Martinetal.,2002).Melatoninblocked
apoptosis and necrosis in 6-OHDA-treated undifferentiated and
nerve growth factor (NGF)-differentiated PC12 cells (Mayo et al.,
1998, 1999). Contrary to these results, striatal DA depletion and
DA neuron loss increased after melatonin treatment of rotenone-
inducedParkinsonism(Tapiasetal.,2010).MelatoningiventoPD
patients improved the duration of sleep and reduced sleep distur-
bances (Dowling et al.,2005). There are no clinical studies to date
that have investigated whether melatonin is neuroprotective for
PD patients.
The antioxidant GSH, which is involved in iron metabolism
andplaysanancillaryroleinthiol–redoxcontrol,isdepletedinthe
SNpcof PDpatients(Perryetal.,1982;Riedereretal.,1989;Pearce
et al., 1997). When GSH was depleted in vitro and in vivo, there
was oxidative damage of complex I proteins (Chinta and Ander-
sen, 2006; Chinta et al., 2007; Kumar et al., 2011), defects in basal
ganglia formed (Sian et al., 1994), and the ubiquitin–proteasome
system functioned poorly (Martin and Teismann, 2009), but the
electron transport chain complex was unaffected (Heales et al.,
2011). Collectively these studies suggest that GSH may facilitate
cascading events leading to oxidative stress (Bharath et al., 2002;
Garrido et al., 2011).
Animal studies have also shown that excessive or reduced GSH
levels can initiate degeneration of DA neurons (Garrido et al.,
2011). However,chronically decreased GSH concentrations in the
brain did not directly correlate to a reduction in the viability of
DA neurons in the SNpc, nor decrease the number of striatal DA
terminals,butdoesmakeneuronsmoresusceptibletoneurotoxins
(Schulz et al., 2000). Treatment with MPTP in GSH peroxidase-
deﬁcient mice resulted in depletion of DA (Klivenyi et al., 2000).
In nigral TH immune responsive cells similar results were seen
with a greater reduction of DA neurons when lower levels of GSH
were present prior to toxin administration (Pileblad et al., 1989;
Seatonetal.,1996;Wullneretal.,1996).Thesestudiessuggestthat
theconcentrationof GSHiskeytoitsneuroprotectivecapabilities.
It has been hypothesized that enhancement of GSH synthesis or
inhibition of its degradation may result in a decrease in disease
progression (Schulz et al.,2000).
Phytic acid (IP6) is a naturally occurring iron chelator in food
that acts by altering cell-signaling pathways and the activity or
expression of antioxidant enzymes (Shamsuddin et al., 1997; Xu
etal.,2011).IP6iscapableof inhibitingMPTP,6-OHDA,andiron
toxicityincellculture(Xuetal.,2008,2011).IP6increasescellsur-
vival in MPTP-treated cells and repressed caspase-3 activity and
DNAfragmentation(Xuetal.,2008).IP6alsosuppressedhydroxyl
radical formation after 1-methyl-4-phenylpyridinium (MPP+)
treatmentinrats(Obata,2003).Furtheranimalandhumanstudies
are needed to test IP6’s antioxidant’s properties.
SEVERAL COMMONLY PRESCRIBED DRUGS ARE EMERGING
AS THERAPEUTIC AGENTS FOR PD
Common household drugs such as aspirin and Ibuprofen protect
againstneuro-inﬂammation,whichcanleadtoneurodegeneration
in the brain (Hirsch and Hunot, 2009). The use of non-steroidal
anti-inﬂammatory drugs (NSAIDS) has been shown to lower the
risk of PD in epidemiological studies (Chen et al.,2003;Ton et al.,
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2006; Wahner et al., 2007; Gao et al., 2011) and protect against
neuronal death, ROS/peroxidation, and dopaminergic neurotoxi-
city by inhibiting cyclo-oxygenase enzymes in animals (Bilodeau
et al., 1995; Kaufmann et al., 1997; Aubin et al., 1998; Saini et al.,
1998; Casper et al., 2000; Sairam et al., 2003). Pretreatment with
NSAIDS is neuroprotective in MPTP and 6-OHDA-treated ani-
mals and in vitro (Esposito et al., 2007). In humans there was a
reduction in PD risk observed in individuals who use Ibuprofen,
but no reduction was found in individuals who use NSAIDS or
Acetaminophen (Chen et al., 2005; Ton et al., 2006; Driver et al.,
2011;Gaoetal.,2011).Acase-controlledstudyalsoconcludedthat
NSAID’s and aspirin show no association with altering the risk
of PD (Becker et al., 2011). In some studies there was a reported
increasedriskofPDobservedinindividualwhouseaspirin(Bower
et al.,2006;Hernan et al.,2006). In contrast,other studies showed
that aspirin was protective and functioned by ROS scavenging
in vivo (Di Matteo et al., 2006; Maharaj et al., 2006b). Ibupro-
fen protects DA neurons against glutamate toxicity and decreases
MPTP toxicity in vitro (Casper et al., 2000; Morioka et al., 2004;
Carrascoetal.,2005).Ameta-analysisdeterminedthatregularuse
of Ibuprofen also reduced the risk of developing PD in humans
by 40% (Samii et al., 2009; Gao et al., 2011). The results from
these studies together suggest that Ibuprofen and aspirin may be
neuroprotective.
The dihydropyridine L-type calcium channel blocker Isradip-
ine has been reported to reduce hypoxia-induced activation of
Ca2+-dependentxanthineoxidases,monoamineoxidases,cytoso-
lic phospholipase A2, and cyclo-oxygenases (COX-2) along with
a decrease in free radical generation and cytochrome-c release
(Barhwal et al., 2009). Increased expression of calpain, caspase-3,
(Barhwaletal.,2009),andglutamate-inducedneurotoxicity(Pizzi
et al.,1991) was also inhibited by Isradipine.
The use of L-type Ca2+ channel antagonists protects SNpc DA
neuronsinMPTP-treatedanimals(Kupschetal.,1995,1996;Chan
et al., 2007), but the same was not true of 6-OHDA-treated ani-
mals(Sautteretal.,1997).Thisdiscrepancymaybetheresultofthe
different mechanisms by which the two toxins act on mitochon-
dria (Bove et al., 2005a). Currently very few studies speciﬁcally
address Isradipine’s neuroprotective capabilities, however a dose-
dependent effect was observed in 6-OHDA-treated animals (Ilijic
et al., 2011). In a pilot study in which PD patients were treated
withIsradipinenonegativesideeffectswerenotedthuspavingthe
way for further clinical testing (Simuni et al.,2010).
Because a mutation in the DJ-1 protein causes early onset
of autosomal PD (Bonifati et al., 2003; Ibanez et al., 2003) and
lower levels of DJ-1 are associated with PD, it is thought that
drugs that up-regulate DJ-1 may slow disease progression by
moderating oxidative stress and protein aggregation (Zhou et al.,
2011). DJ-1 acts through multiple pathways, and works in par-
allel with PINK1/parkin (Zhou et al., 2011). Phenylbutyrate, a
chaperone molecule and histone deacetylase inhibitor, increased
DJ-1 expression in DA cell cultures, rescued cells from oxida-
tive stress, and reduced α-synuclein aggregation (Zhou et al.,
2011). In MPTP-treated animals, phenylbutyrate protected DA
neurons in the SNpc and increase DJ-1 expression (Gardian
et al., 2004; Zhou et al., 2011). Long-term administration of
phenylbutyrate reduced deterioration in motor and cognitive
functions in mice (Zhou et al., 2011). Similar results were seen
with 4-phenylbutyrate in rotenone-treated mice (Inden et al.,
2007).
Type 2 diabetes has been correlated with an increase risk of
PD and a high prevalence of insulin resistance has been found
in PD patients,suggesting that the two chronic diseases may share
similardysregulatedpathwaysthatplayaroleincelldeathanddys-
function (Arvanitakis et al.,2004;Jeerakathil et al.,2007). Possible
shared pathways may be related to insulin regulation, suggest-
ing that diabetes drugs may possess neuroprotective effects (Holst
et al., 2011). Glucagon-like peptide-1 (GLP-1) is commonly used
to treat type 2 diabetes. GLP-1 also acts as a growth factor in
the brain, and can induce neurite outgrowth and protect against
oxidative injury in cultured neuronal cells (Perry et al., 2007).
The anti-apoptotic actions of GLP-1 is thought to be related to
theactivationof thetranscriptionfactorcAMPresponseelement-
binding protein by phosphorylation (Perry et al., 2002; Li et al.,
2009). Previous studies have also claimed that PDA, PI3K, and
MAPK may be involved in the mechanism of action of GLP-1,
in addition to MAPK-independent signaling and growth factor-
dependent Ser/Thr kinase AktPKB (Lazaroff et al., 1995; During
et al.,2003; Perry and Greig, 2005).
Exendin-4 (Ex-4), an analog of GLP-1, protected DA neurons
from degeneration, preserved DA levels, and improved motor
function in rodents (Li et al., 2009) by inhibiting microglial acti-
vation and matrix metalloproteinase-3 expression (Kim et al.,
2009). Ex-4 has also been shown to protect ventral mesencephalic
dopaminergic cells in culture, reverse nigral lesions, and pro-
tect against 6-OHDA toxicity (Harkavyi et al., 2008; Li et al.,
2009). Ex-4 receptors also show neuroprotection by mediating
and increasing neurogenesis in the subventricular zone in rodents
(Bertilssonetal.,2008).InadditiontoEx-4,otheranalogsof GLP-
1 offer promising neurprotective effects (see review Harkavyi and
Whitton, 2010). One of these, Liraglutide, has been shown to be
neuroprotective in an Alzheimer’s disease model (McClean et al.,
2010, 2011).
RASAGILINE AND MINOCYCLINE ARE CURRENTLY IN
CLINICAL TRIALS AS NEUROPROTECTIVE AGENTS FOR PD
Rasagiline is a selective and potent propargylamine MAO-B
inhibitor (Tatton et al., 2003), that reduces MPTP and 6-OHDA
toxicity in PC12 and SH-SY5Y cells, (Maruyama et al., 2000) and
isneuroprotectiveinvivo (Heikkilaetal.,1985;Huangetal.,1999;
Speiser et al., 1999; Sagi et al., 2001; Youdim et al., 2001a). Pre-
treatment with Rasagiline prevents nigrostriatal damage induced
by MPTP in primates (Kupsch et al., 2001; Sagi et al., 2001).
Chronic administration of Rasagiline increased DA neuron sur-
vival in lesioned SNpc and improved motor impairments (Blan-
dini et al., 2004). Rasagiline also increased the expression of the
neurotrophins BDNF, GDNF, and NGF (Murer et al., 2001). In
humans,Rasagilinereducedthelong-termprogressionandsymp-
toms in PD (Hauser et al.,2009;Olanow et al.,2009). In a promis-
ing recent study,Rasagiline delayed the need for antiparkinsonian
drugs and patients had lower scores on the PD rating scale in a
Phase III study (Rascol et al.,2011).
Rasagiline suppresses mitochondrial apoptosis by inhibit-
ing caspase-3 and nuclear poly [ADP-ribose] polymerase 1
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Table 1 | Neuroprotective agents in PD models.
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
Caffeine A (van den Pol, 1986;
Kachroo et al., 2010)
Decreased dopaminergic neuron
toxicity in MPTP
E( Ross et al., 2000; Ascherio
et al., 2001)*, (Saaksjarvi et al.,
2008; Costa et al., 2010)*
Caffeinated beverages
decreased the risk of PD
A( Chen et al., 2001;
Joghataie et al., 2004;
Aguiar et al., 2006)
Decreased DA loss and restored
DA levels in MPTP and 6-OHDA
E( Xu et al., 2006) Caffeinated beverages have
no effect on PD risk
A( Joghataie et al., 2004;
Aguiar et al., 2006)
Decreased motor dysfunctions in
6-OHDA
H( Ascherio et al., 2003) A decrease in PD risk among
women consuming caffeine
and not taking hormone-
replacement therapy A( Xu et al., 2002, 2010) Caffeine increased metabolites
associated with prevention of DA
loss
A( Xu et al., 2006) Estrogen and caffeine prevented
neuroprotection
Caffeine+
nicotine
A( Trinh et al., 2010) Decaffeinated coffee and
nicotine-free tobacco were
neuroprotective in Drosophila
E( Tan et al., 2003) Caffeine and nicotine com-
bined reduced the rate of PD
Nicotine A (Ferger et al., 1998;
Costa et al., 2001)
Nicotine reduced DA depletion
resulting from MPTP and 6-OHDA
E( Quick, 2004; Simon et al.,
2009)
Nicotine lowered the risk of
developing PD
A( Meshul et al., 2002) Nicotine minimized parkinsonian
contralateral rotations in 6-OHDA
A( Quik et al., 2006) Non-human primates maintained
dopaminergic function and cell
loss in the SNpc was prevented
with nicotine administration
A( Carr and Rowell, 1990)* Tobacco smoke prior to MPTP
treatment reduced the loss of
striatal DA in mice
Urate and UA A/C (Jones et al., 2000;
Duan et al., 2002)
UA protects against DA-induced
apoptosis
E( de Lau et al., 2005; Alonso
et al., 2007; Annanmaki et al.,
2007; Chen et al., 2009)*,
(Schwarzschild et al., 2008)*,
(Andreadou et al., 2009)*
Decreased risk of PD with
UA and urate
H( Ascherio et al., 2009) Slower rates of clinical pro-
gression of PD were seen
with UA intake
H( de Lau et al., 2005;
Schwarzschild et al., 2008)
Serum UA correlates with a
decreased risk of PD
Vitamin E A (Odunze et al., 1990) Vitamin E deﬁciency increases
MPTP toxicity
E( Zhang et al., 2002; Etminan
et al., 2005)*
Protection from PD with
moderate vitamin E intake
A( Lan and Jiang, 1997;
Roghani and Behzadi,
2001)
Vitamin E supplementation
protected DA neurons in the SNpc
and reduced DA loss
H( Fernandez-Calle et al., 1992;
LeWitt, 1994; Morens et al.,
1996)
Clinical trials also show no
neuroprotective beneﬁt of
taking vitamin E
A( Gong et al., 1991; Chi
et al., 1992)
Striatal DA was not attenuated by
pretreatment of vitamin E
C( Offen et al., 1996) Vitamin E has no protective effects
against DA-induced toxicity in
PC12 cells
A( Perry et al., 1987) Vitamin E partially protected DA
neurons in MPTP rodents
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
Vitamin E+
vitamin C
H( Fahn, 1992) Both vitamins combined
decreased PD progression
in early stage patients
Vitamin C H( Scheider et al., 1997; Zhang
et al., 2002; Etminan et al., 2005)
Few beneﬁcial effects are
seenwithvitaminCandeven
an increased risk of PD
H( Perlmutter, 1988) Vitamin C intake reduced the
risk of PD by 40%
Vitamin D C (Butler et al., 2011) Disruption of Vitamin D’s Ca2+
homeostasis properties
accelerated SNpc dopaminergic
neuron loss
E( Anderson et al., 1999) An increased risk of PD is
associated with high con-
sumption of vitamin D
H/A (Gash et al., 1996;
Kordower et al., 2000), (Gill
et al., 2003)
GDNF stimulation by Vitamin D
can alleviated PD symptoms in
primates and PD patients
C/A (Wang et al., 2001;
Smith et al., 2006)
Vitamin D produced beneﬁcial
effects against PD characteristics
A( Holick, 2007) Vitamin D increased
neuromuscular function in
parkinsonian rodents
Beta-carotene (Perry et al., 1985, 1987;
Yong et al., 1986)
Beta-carotene protected against
MPTP neurotoxicity in mice, but
not primates
E( Perlmutter, 1988) A decrease in the risk of
PD was seen with high B-
carotene intake
Riboﬂavin E( Perlmutter, 1988; Murakami
et al., 2010)
ReducedriskofPD,withhigh
riboﬂavin intake by 51%
E( Coimbra and Junqueira, 2003) Riboﬂavin supplementation
improved motor capacity of
PD patients
CoQ10 A (Shults et al., 1999) CoQ10 protected nigrostriatal
dopaminergic neurons in MPTP
H( Shults et al., 2002; Shults,
2003; Galpern and Cudkowicz,
2007)
Chronic administration of
CoQ10 delayed progression
of PD in patients with no
adverse affects in Phase II
A( Cleren et al., 2008) CoQ10 supplementation
diminished neural tissue damage
and prevented DA depletion in
SNpc
Investigators (2007) Inconclusive results of
CoQ10 supplement show-
ing neuroprotection in PD
patients
CoQ10+
vitamin E
H( Shults et al., 2004) Combination showed bene-
ﬁcial for PD patients, how-
ever, Phase III trials deemed
it futile (NINDS, see text
footnote 1)
Creatine A (Matthews et al., 1999) Creatine protected against
MPTP-induced DA depletion in the
SNpc
Investigators (2006) Creatine delayed the pro-
gression of PD by 50%
Investigators (2008) Creatine showed efﬁcacy as
a neuroprotective agent in
PD and is currently in Phase
III trials (NET-PDLS, see text
footnote 2)
CoQ10+
creatine
A/H (Yang et al., 2009) Combination showed a
neuroprotective effect in chronic
MPTP and humans
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
DHA A (Bousquet et al., 2008) DHA supplements replaced omega-6 fatty
acids after MPTP
C( Wang et al., 2003) Neurons were protected against
cytotoxicity with DHA intake
A( Ozsoy et al., 2011) DHA decreased apoptosis of dopaminergic
cells in MPTP
A( Samadi et al., 2006) DHA reduced 40% of the levodopa-induced
dyskinesias in Parkinsonian primates
A( Bousquet et al., 2008) DHA preserved DA levels from
MPTP-induced neurotoxicity in mice
DHA+uridine A (Wurtman et al., 2006;
Sakamoto et al., 2007)
This combination increased levels of neural
phosphatides, proteins in synaptic
membranes, and dendritic spines in rodents
A( Cansev et al., 2008) DHA and uridine administration also
reduced parkinsonian related behaviors and
elevated DA levels in 6-OHDA rats
Melatonin A (Acuna-Castroviejo et al.,
1997; Kim et al., 1998;
Maharaj et al., 2006a)
Neuronal cell death damage induced by
MPTP , 6-OHDA, and iron was protected
with Melatonin administration
H( Dowling et al., 2005) Melatoninimprovedduration
of sleep and reduced sleep
disturbances in PD patients
A( Mayo et al., 1998, 1999) Melatonin blocked apoptosis and necrosis
in 6-OHDA and PC12 cells
A( Tapias et al., 2010) Striatal DA depletion and DA neuron loss
increased after melatonin treatment of
rotenone-induced Parkinsonism
GSH A (Garrido et al., 2011) Excessive or reduced GSH levels initiated
degeneration of DA neurons
C( Schulz et al., 2000) Decreased GSH increased neuron
susceptibility to neurotoxins, but did not
correlate to DA viability or striatal terminals
A( Klivenyi et al., 2000) Depletion of DA was seen after MPTP
treatment in GSH peroxidase-deﬁcient mice
A( Pileblad et al., 1989;
Seaton et al., 1996;
Wullner et al., 1996)
Low levels of GSH reduced DA neurons
after toxin administration
IP6 A/C (Xu et al., 2008, 2011) IP6 inhibited MPTP , 6-OHDA, and iron
toxicity in cell culture
A( Xu et al., 2008) IP6 increased cell survival in MPTP
A( Obata, 2003) IP6 suppressed hydroxyl radical formation
after MPP+ treatment in rats
NSAID (ibupro-
fen +aspirin)
A/C (Bilodeau et al., 1995;
Kaufmann et al., 1997;
Aubin et al., 1998; Saini
et al., 1998; Casper et al.,
2000; Sairam et al., 2003)
NSAID’s protected against neuronal death
and dopaminergic neurotoxicity
E( Chen et al., 2003;Ton
et al., 2006; Wahner
et al., 2007; Gao et al.,
2011)
NSAID’s lowered the risk of
PD
E( Chen et al., 2005;Ton
et al., 2006; Driver
et al., 2011; Gao et al.,
2011)
A reduction in PD risk was
observed with Ibuprofen,
but not NSAIDS or Aceta-
minophen
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
A/C (Esposito et al., 2007) NSAIDS showed neuroprotection
in MPTP , 6-OHDA, and in vitro
E( Becker et al., 2011) NSAID’s and aspirin showed
no association with altering
the risk of PD
A( Casper et al., 2000;
Morioka et al., 2004,
Carrasco et al., 2005)
Ibuprofen protected DA neurons
against glutamate toxicity and
decreased MPTP toxicity
E( Bower et al., 2006; Hernan
et al., 2006)
Increased risk of PD shown
with moderate aspirin intake
E( Samii et al., 2009; Gao et al.,
2011)
Ibuprofen reduced the risk of
developing PD in humans by
40%
Isradipine A (Ilijic et al., 2011) Isradipine showed
neuroprotection against 6-OHDA
H( Simuni et al., 2010) Isradipine was deemed futile
for human trials
Phenylbutyrate C (Gardian et al., 2004;
Zhou et al., 2011)
Phenylbutyrate protected DA
neurons in the SNpc
A( Zhou et al., 2011) Reduced deterioration in motor
and cognitive function in mice
Ex-4 A (Li et al., 2009) Protected DA neuron
degeneration, preserved DA
levels, and improved motor
function in rodents
A/C (Harkavyi et al., 2008;
Li et al., 2009)
Ex-4 protected ventral
mesencephalic dopaminergic cells
in culture, reverse nigral lesions,
and protected against 6-OHDA
toxicity
Rasagiline C:, (Heikkila et al., 1985;
Huang et al., 1999; Speiser
et al., 1999; Maruyama
et al., 2000; Sagi et al.,
2001;Youdim et al., 2001a)
Reduces MPTP and 6-OHDA
toxicity in PC12 and SH-SY5Y cells
H( Hauser et al., 2009; Olanow
et al., 2009)
Rasagiline reduced the long-
term progression and symp-
toms in PD
A( Kupsch et al., 2001; Sagi
et al., 2001).
Rasagiline prevented nigrostriatal
damage induced by MPTP in
primates
A( Blandini et al., 2004) Rasagiline increased DA neuron
survival in lesioned SNpc and
improved motor impairments
H( Rascol et al., 2011) Rasagiline in a Phase
III delayed the need for
antiparkinsonian drugs and
patients had lower scores
on the Parkinson’s disease
rating scale
C( Murer et al., 2001) Rasagiline increased expression of
neurotrophins
Minocycline A/C (Du et al., 2001). Minocycline blocked
MPTP-induced degeneration of DA
neurons in the SNpc∼ preventing
loss of striatal DA and its
metabolites. Minocycline
treatment also inhibited MPP+
mediated inducible NO synthase
expression in vivo and blocked
NO-induced neurotoxicity in vitro
H( Investigators, 2006) Minocycline was deemed
effective in Phase II slow-
ing the progression of PD in
patients. An 18-month follow
up study showed no safety
concerns with its use (Inves-
tigators, 2008), leading to
Phase III trials
(Continued)
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Table 1 | Continued
Neuroprotective
agents
Cell culture and animal studies Human and epidemiological studies
Study Results Study Results
A( Faust et al., 2009;
Radad et al., 2010)
DA neuroprotection by
Minocycline was seen in a
Drosophila model of PD and after
rotenone toxicity in rodents
A( Quintero et al., 2006). Reduced the number of
apomorphine-induced rotations in
6-OHDA-lesioned rats
A/C (Yang
et al., 2003)
Minocycline exacerbated MPTP
damage to DA neurons in vitro and
in vivo
A( Diguet et al., 2004) Minocycline treatment in primates
and mice produced more
severe/rapid parkinsonism,
behavior deﬁcits, and greater loss
of nerve endings
Minocycline+
creatine
H( NET-PD, 2006) Reduced progression in PD
patients in Phase II
C, cell culture; A, animal; H, human; and E, epidemiological. Studies showing gender speciﬁcity, where males show favorable results are denoted (*).
(PARP-1)activation,translocationof glyceraldehyde-3-phosphate
dehydrogenase(GAPDH),theopeningof theMPTandDNAfrag-
mentation (Figure1;Youdim and Weinstock,2001;Youdim et al.,
2001b,2003;Akao et al.,2002a; BarAm et al.,2004; Bar-Am et al.,
2004; Weinreb et al., 2004). Rasagiline also increases the expres-
sion of the anti-apoptotic proteins Bcl-2 and B-cell lymphoma-
extra large (Bcl-XL) through the PKC pathway, in addition to
down-regulating the pro-apoptotic Bcl-2-associated death pro-
moter(Bad)andBcl-2-associatedXprotein(BAX)(Youdimetal.,
2001a, 2003; Akao et al., 2002b;Yogev-Falach et al., 2003; Bar Am
et al.,2004; Bar-Am et al.,2004;Weinreb et al.,2004).
Minocyclineisasemi-syntheticsecond-generationtetracycline
that exerts anti-inﬂammatory and antioxidant effects (Ryan and
Ashley, 1998; Ryan et al., 1998; Faust et al., 2009). Minocycline
works by inhibiting the activation of microglia and attenuating
thep38MAPKcascadewhichreducesinﬂammatorycytokinesyn-
thesis (Figure 1; Yrjanheikki et al., 1998; Tikka et al., 2001; Wu
etal.,2002).ItisthoughtthatMinocycline’sneuroprotectiveprop-
erties may result from inhibition of NO-mediated neurotoxicity
(Du et al.,2001).Additionally,Minocycline may be able to chelate
metal ions.
In rodents, Minocycline blocked MPTP-induced degeneration
of DA neurons in the SNpc, preventing loss of striatal DA, and its
metabolites (Du et al., 2001). Minocycline treatment also inhib-
ited MPP+ mediated inducible NO synthase expression in vivo
and potently blocked NO-induced neurotoxicity in vitro (Du
et al., 2001). Potent DA neuroprotection by Minocycline was
also observed in a Drosophila model of PD (Faust et al., 2009)
and after chronic rotenone toxicity in rodents (Radad et al.,
2010).Inaddition,Minocyclineadministrationreducedthenum-
ber of apomorphine-induced rotations in 6-OHDA-lesioned rats,
reduced TH-positive cell loss and increased the size and ﬁber
density of the remaining nigral cells (Quintero et al., 2006).
Although Minocycline inhibits microglial activation (Wu et al.,
2002), other studies have shown it to signiﬁcantly exacerbate
MPTP-induced damage to DA neurons in vitro and in vivo (Yang
et al., 2003). Similarly, Minocycline treatment of monkeys and
mice produced more severe and rapid parkinsonism, behavior
deﬁcits, and greater loss of nerve endings (Diguet et al., 2004).
Lack of neuroprotection was shown to be due to the inability of
Minocycline to abolish the activation of TNF-α and its receptors,
therebyfailingtomodulateTNFsignalingafterMPTPadministra-
tion (Sriram et al., 2006). Minocycline administration in TNF-α
knockout MPTP-treated mice increased leakage of the BBB, but
theseanimalsdidnotexhibitagreaterlossof neurons(Zhaoetal.,
2007).InaphaseIIclinicaltrial,Minocyclinewasdeemedeffective
in slowing the progression of PD in patients (Investigators, 2006)
andan18-monthfollowupstudyshowednosafetyconcerns,thus
paving the way to a phase III trial (Investigators, 2008). Addi-
tionally, neuroprotective effects of Minocycline combined with
creatinedemonstrateadditivebeneﬁtsinreducingPDprogression
in patients, and is currently in clinical trials (NET-PD, 2006).
CONCLUDING REMARKS
Some neuroprotective agents show promising results for slowing
the progression of PD and these are summarized in Table 1.I n
general, these agents reduce oxidative stress, mitochondrial dys-
function, protein aggregation, inﬂammation, excitotoxicity, cell
death, iron accumulation, or stimulate neurotrophic factors. In
an earlier review, caffeine, CoQ10, creatine, Minocycline, and
Rasagiline were identiﬁed as the top candidates for preventing
neurodegenerativediseases(Ravinaetal.,2003).However,current
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researchsuggeststhatMinocycline,creatine,andRasagilinearethe
mostpromisingagentsforneuroprotectioninPDandallthreeare
now in Phase III trials. In addition,a combination of Minocycline
and creatine is in Phase III trials and CoQ10 and creatine is in
Phase II. Other promising neuroprotective agents for PD include
nicotine, caffeine, Ibuprofen, and DHA since they show strong
neuroprotection. More moderate protective effects are observed
with melatonin, vitamin D, and UA. In contrast, vitamin E, vit-
amin C, NSAIDs, aspirin, GSH, and CoQ10 alone show limited
and/or inconsistent results for slowing disease progression. Of the
remainingagents,IP6,riboﬂavin,beta-carotene,Liraglutide,Ex-4,
Phenylbutyrate, and Isradipine show promising results in reduc-
ing the risk of PD, but further studies are needed to determine if
theyareneuroprotectiveinhumans.Additionally,caffeineandUA
maybepromising,butonlyinmalePDpatients.Thesesex-speciﬁc
effectsareareminderthatitisimportanttoassesseachPDpatient’s
response to neuroprotective agents clinically since other uniden-
tiﬁed variables, such as single nucleotide polymorphisms (SNPs)
and hormones, may also affect an individual’s response. Further
researchaddressingthemechanismof thesexdifferencesandhow
SNPsplayaroleintheresponsetoneuroprotectiveagentsisneeded
to optimize a therapeutic approach for treating PD.
ACKNOWLEDGMENTS
TheauthorsthankJoseSantiagoandMichBealesforcriticalreview
of the manuscript. This work was supported by the US Army
Medical Research and Materiel Command under award number
W81XWH-09-0708. Opinions, conclusions, interpretations and
recommendations are those of the author and are not necessarily
endorsed by the U.S. Army.
REFERENCES
Abdin, A. A., and Hamouda, H. E.
(2008). Mechanism of the neuro-
protective role of coenzyme Q10
withorwithoutL-dopainrotenone-
induced parkinsonism. Neurophar-
macology 55, 1340–1346.
Acuna-Castroviejo, D., Coto-Montes,
A., Gaia Monti, M., Ortiz, G.
G., and Reiter, R. J. (1997).
Melatonin is protective against
MPTP-induced striatal and hip-
pocampal lesions. Life Sci. 60,
PL23–PL29.
Adhihetty, P. J., and Beal, M. F. (2008).
Creatine and its potential therapeu-
ticvaluefortargetingcellularenergy
impairment in neurodegenerative
diseases. Neuromolecular Med. 10,
275–290.
Aguiar, L. M., Nobre, H. V. Jr.,
Macedo, D. S., Oliveira, A. A., Fre-
itas, R. M., Vasconcelos, S. M.,
Cunha, G. M., Sousa, F. C., and
Viana, G. S. (2006). Neuroprotec-
tive effects of caffeine in the model
of 6-hydroxydopamine lesion in
rats. Pharmacol. Biochem. Behav. 84,
415–419.
Akao, Y., Maruyama, W., Shimizu, S.,
Yi, H., Nakagawa, Y., Shamoto-
Nagai, M., Youdim, M. B., Tsuji-
moto, Y., and Naoi, M. (2002a).
Mitochondrial permeability transi-
tion mediates apoptosis induced by
N-methyl(R)salsolinol, an endoge-
nous neurotoxin,and is inhibited by
Bcl-2 and rasagiline, N-propargyl-
1(R)-aminoindan. J. Neurochem. 82,
913–923.
Akao, Y., Maruyama, W., Yi, H.,
Shamoto-Nagai, M., Youdim, M.
B., and Naoi, M. (2002b). An
anti-Parkinson’s disease drug, N-
propargyl-1(R)-aminoindan (rasag-
iline), enhances expression of anti-
apoptotic bcl-2 in human dopamin-
ergic SH-SY5Y cells. Neurosci. Lett.
326, 105–108.
Akbar, M., Calderon, F., Wen, Z.,
and Kim, H. Y. (2005). Docosa-
hexaenoicacid:apositivemodulator
of Akt signaling in neuronal sur-
vival. Proc. Natl. Acad. Sci. U.S.A.
102, 10858–10863.
Akbar, M., and Kim, H. Y. (2002). Pro-
tective effects of docosahexaenoic
acid in staurosporine-induced
apoptosis: involvement of
phosphatidylinositol-3 kinase
pathway. J. Neurochem. 82,655–665.
Alonso, A., Rodriguez, L. A., Logros-
cino, G., and Hernan, M. A. (2007).
Gout and risk of Parkinson disease:
a prospective study. Neurology 69,
1696–1700.
Ames, B. N., Cathcart, R., Schwiers,
E., and Hochstein, P. (1981). Uric
acidprovidesanantioxidantdefense
in humans against oxidant- and
radical-caused aging and cancer: a
hypothesis. Proc. Natl. Acad. Sci.
U.S.A. 78, 6858–6862.
Anderson, C., Checkoway, H., Franklin,
G.M.,Beresford,S.,Smith-Weller,T.,
and Swanson, P. D. (1999). Dietary
factors in Parkinson’s disease: the
role of food groups and speciﬁc
foods. Mov. Disord. 14, 21–27.
Andreadou, E., Nikolaou, C.,
Gournaras, F., Rentzos, M., Bouﬁ-
dou, F., Tsoutsou, A., Zournas, C.,
Zissimopoulos, V., and Vassilopou-
los,D. (2009). Serum uric acid levels
in patients with Parkinson’s disease:
their relationship to treatment
and disease duration. Clin. Neurol.
Neurosurg. 111, 724–728.
Annanmaki, T., Muuronen, A., and
Murros, K. (2007). Low plasma uric
acid level in Parkinson’s disease.
Mov. Disord. 22, 1133–1137.
Antolin, I., Mayo, J. C., Sainz, R. M.,
del Brio Mde,L.,Herrera,F.,Martin,
V.,andRodriguez,C.(2002).Protec-
tive effect of melatonin in a chronic
experimental model of Parkinson’s
disease. Brain Res. 943, 163–173.
Arvanitakis, Z., Wilson, R. S., Bienias,
J. L., Evans, D. A., and Bennett, D.
A.(2004).Diabetesmellitusandrisk
of Alzheimer disease and decline in
cognitive function. Arch. Neurol. 61,
661–666.
Ascherio, A., Chen, H., Schwarzschild,
M. A., Zhang, S. M., Colditz, G. A.,
and Speizer, F. E. (2003). Caffeine,
postmenopausal estrogen, and risk
of Parkinson’sdisease.Neurology 60,
790–795.
Ascherio,A.,LeWitt,P.A.,Xu,K.,Eberly,
S.,Watts,A., Matson,W. R., Marras,
C., Kieburtz, K., Rudolph, A., Bog-
danov, M. B., Schwid, S. R., Tennis,
M., Tanner, C. M., Beal, M. F., Lang,
A. E., Oakes, D., Fahn, S., Shoulson,
I., and Schwarzschild, M. A. (2009).
Urate as a predictor of the rate of
clinical decline in Parkinson disease.
Arch. Neurol. 66, 1460–1468.
Ascherio, A., Zhang, S. M., Hernan,
M. A., Kawachi, I., Colditz, G. A.,
Speizer, F. E., and Willett, W. C.
(2001). Prospective study of caffeine
consumptionandriskofParkinson’s
disease in men and women. Ann.
Neurol. 50, 56–63.
Aubin, N., Curet, O., Deffois, A., and
Carter,C.(1998).Aspirinandsalicy-
late protect against MPTP-induced
dopamine depletion in mice. J. Neu-
rochem. 71, 1635–1642.
BarAm,O.,Amit,T.,andYoudim,M.B.
(2004).Contrastingneuroprotective
and neurotoxic actions of respective
metabolites of anti-Parkinson drugs
rasagiline and selegiline. Neurosci.
Lett. 355, 169–172.
Bar-Am, O.,Yogev-Falach, M.,Amit, T.,
Sagi, Y., and Youdim, M. B. (2004).
Regulation of protein kinase C by
the anti-Parkinson drug, MAO-B
inhibitor, rasagiline and its deriv-
atives, in vivo. J. Neurochem. 89,
1119–1125.
Barhwal, K., Hota, S. K., Baitharu,
I., Prasad, D., Singh, S. B., and
Ilavazhagan, G. (2009). Isradip-
ine antagonizes hypobaric hypoxia
induced CA1 damage and memory
impairment: complementary roles
of L-type calcium channel and
NMDAreceptors.Neurobiol.Dis.34,
230–244.
Bazan,N.G.(2005).NeuroprotectinD1
(NPD1): a DHA-derived mediator
thatprotectsbrainandretinaagainst
cell injury-induced oxidative stress.
Brain Pathol. 15, 159–166.
Beal, M. F., and Shults, C. W. (2003).
Effects of coenzyme Q10 in Hunt-
ington’s disease and early Parkin-
son’sdisease.Biofactors 18,153–161.
Becker, C., Jick, S. S., and Meier, C.
R. (2011). NSAID use and risk
of Parkinson disease: a population-
basedcase-controlstudy.Eur.J.Neu-
rol. 18, 1336–1342.
Bertilsson, G., Patrone, C., Zachris-
son, O., Andersson, A., Dannaeus,
K., Heidrich, J., Kortesmaa, J., Mer-
cer, A., Nielsen, E., Ronnholm, H.,
and Wikstrom, L. (2008). Peptide
hormone exendin-4 stimulates sub-
ventricular zone neurogenesis in
the adult rodent brain and induces
recovery in an animal model of
Parkinson’s disease. J. Neurosci. Res.
86, 326–338.
Bharath, S., Hsu, M., Kaur, D.,
Rajagopalan, S., and Andersen, J.
K. (2002). Glutathione, iron and
Parkinson’s disease. Biochem. Phar-
macol. 64, 1037–1048.
Bilodeau, J. F., Wang, M., Chung, F. L.,
and Castonguay, A. (1995). Effects
of nonsteroidal antiinﬂammatory
drugs on oxidative pathways in A/J
mice. Free Radic. Biol. Med. 18,
47–54.
Blandini, F., Armentero, M. T., Fan-
cellu, R., Blaugrund, E., and Nappi,
G. (2004). Neuroprotective effect
of rasagiline in a rodent model of
Parkinson’sdisease.Exp.Neurol.187,
455–459.
Frontiers in Neurology | Neuropharmacology November 2011 | Volume 2 | Article 68 | 12Seidl and Potashkin Neuroprotection in Parkinson’s disease
Bonifati, V., Rizzu, P., Squitieri, F.,
Krieger, E., Vanacore, N., van Swi-
eten,J.C.,Brice,A.,vanDuijn,C.M.,
Oostra, B., Meco, G., and Heutink,
P. (2003). DJ-1(PARK7), a novel
gene for autosomal recessive, early
onset parkinsonism. Neurol. Sci. 24,
159–160.
Bousquet, M., Calon, F., and Cicchetti,
F. (2011). Impact of omega-3 fatty
acids in Parkinson’s disease. Ageing
Res. Rev. 10, 453–463.
Bousquet, M., Saint-Pierre, M., Julien,
C., Salem, N. Jr., Cicchetti, F., and
Calon, F. (2008). Beneﬁcial effects
of dietary omega-3 polyunsaturated
fattyacidontoxin-inducedneuronal
degeneration in an animal model
of Parkinson’s disease. FASEB J. 22,
1213–1225.
Bove, J., Prou, D., Perier, C., and Przed-
borski, S. (2005a). Toxin-induced
models of Parkinson’s disease. Neu-
roRx 2, 484–494.
Bove, J., Serrats, J., Mengod, G., Cortes,
R.,Tolosa,E.,andMarin,C.(2005b).
Neuroprotection induced by the
adenosine A2A antagonist CSC in
the 6-OHDA rat model of parkin-
sonism: effect on the activity of stri-
ataloutputpathways.Exp.BrainRes.
165, 362–374.
Bower, J. H., Maraganore, D. M., Peter-
son, B. J., Ahlskog, J. E., and Rocca,
W. A. (2006). Immunologic dis-
eases, anti-inﬂammatory drugs, and
Parkinson disease: a case-control
study. Neurology 67, 494–496.
Burton, G. W., Joyce, A., and Ingold,
K. U. (1983). Is vitamin E the
only lipid-soluble, chain-breaking
antioxidant in human blood plasma
and erythrocyte membranes? Arch.
Biochem. Biophys. 221, 281–290.
Butler, M. W., Burt, A., Edwards, T. L.,
Zuchner, S., Scott, W. K., Martin, E.
R.,Vance,J.M.,andWang,L.(2011).
Vitamin D receptor gene as a candi-
dategeneforParkinsondisease.Ann.
Hum. Genet. 75, 201–210.
Calon, F., Lim, G. P., Morihara, T.,
Yang, F., Ubeda, O., Salem, N. Jr.,
Frautschy, S. A., and Cole, G. M.
(2005). Dietary n-3 polyunsatu-
rated fatty acid depletion activates
caspases and decreases NMDA
receptors in the brain of a trans-
genic mouse model of Alzheimer’s
disease. Eur. J. Neurosci. 22,
617–626.
Calon, F., Lim, G. P.,Yang, F., Morihara,
T., Teter, B., Ubeda, O., Rostaing, P.,
Triller, A., Salem, N. Jr., Ashe, K. H.,
Frautschy, S. A., and Cole, G. M.
(2004). Docosahexaenoic acid pro-
tects from dendritic pathology in an
Alzheimer’s disease mouse model.
Neuron 43, 633–645.
Cansev,M.,Ulus,I.H.,Wang,L.,Maher,
T. J., and Wurtman, R. J. (2008).
Restorative effects of uridine plus
docosahexaenoic acid in a rat model
of Parkinson’s disease. Neurosci. Res.
62, 206–209.
Carr, L. A., and Rowell, P. P. (1990).
Attenuation of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-induced
neurotoxicity by tobacco
smoke. Neuropharmacology 29,
311–314.
Carrasco, E., Casper, D., and Werner, P.
(2005).Dopaminergicneurotoxicity
by 6-OHDA and MPP+: differential
requirement for neuronal cyclooxy-
genase activity. J. Neurosci. Res. 81,
121–131.
Casper, D., Yaparpalvi, U., Rempel,
N., and Werner, P. (2000). Ibupro-
fen protects dopaminergic neurons
against glutamate toxicity in vitro.
Neurosci. Lett. 289, 201–204.
Chan,C. S.,Gertler,T. S.,and Surmeier,
D. J. (2009). Calcium homeostasis,
selective vulnerability and Parkin-
son’s disease. Trends Neurosci. 32,
249–256.
Chan, C. S., Guzman, J. N., Ilijic, E.,
Mercer, J. N., Rick, C., Tkatch, T.,
Meredith, G. E., and Surmeier, D. J.
(2007). ‘Rejuvenation’ protects neu-
ronsinmousemodelsof Parkinson’s
disease. Nature 447, 1081–1086.
Cheeseman, K. H., Emery, S., Maddix,
S. P., Slater, T. F., Burton, G. W., and
Ingold,K.U.(1988).Studiesonlipid
peroxidation in normal and tumour
tissues.TheYoshidaratlivertumour.
Biochem. J. 250, 247–252.
Chen, H., Jacobs, E., Schwarzschild,
M. A., McCullough, M. L., Calle,
E. E., Thun, M. J., and Ascherio,
A. (2005). Nonsteroidal antiinﬂam-
matory drug use and the risk for
Parkinson’s disease. Ann. Neurol. 58,
963–967.
Chen, H., Mosley, T. H., Alonso, A.,
and Huang, X. (2009). Plasma urate
and Parkinson’s disease in the ath-
erosclerosis risk in communities
(ARIC) study. Am. J. Epidemiol. 169,
1064–1069.
Chen, H., Zhang, S. M., Hernan, M.
A., Schwarzschild, M. A., Willett,
W. C., Colditz, G. A., Speizer, F.
E., and Ascherio, A. (2003). Non-
steroidal anti-inﬂammatory drugs
and the risk of Parkinson disease.
Arch. Neurol. 60, 1059–1064.
Chen, J. F., Xu, K., Petzer, J. P., Staal,
R., Xu, Y. H., Beilstein, M., Son-
salla, P. K., Castagnoli, K., Castag-
noli,N.Jr.,andSchwarzschild,M.A.
(2001). Neuroprotection by caffeine
and A(2A) adenosine receptor inac-
tivation in a model of Parkinson’s
disease. J. Neurosci. 21, RC143.
Chi, D. S., Gong, L., Daigneault, E. A.,
and Kostrzewa,R. M. (1992). Effects
of MPTP and vitamin E treatments
on immune function in mice. Int. J.
Immunopharmacol. 14, 739–746.
Chinta,S. J.,andAndersen,J. K. (2006).
Reversible inhibition of mitochon-
drial complex I activity following
chronic dopaminergic glutathione
depletion in vitro: implications for
Parkinson’s disease. Free Radic. Biol.
Med. 41, 1442–1448.
Chinta, S. J., Kumar, M. J., Hsu, M.,
Rajagopalan, S., Kaur, D., Rane,
A., Nicholls, D. G., Choi, J., and
Andersen, J. K. (2007). Inducible
alterations of glutathione levels in
adult dopaminergic midbrain neu-
rons result in nigrostriatal degener-
ation. J. Neurosci. 27, 13997–14006.
Choi,H.K.,Atkinson,K.,Karlson,E.W.,
Willett, W., and Curhan, G. (2004).
Alcohol intake and risk of incident
gout in men: a prospective study.
Lancet 363, 1277–1281.
Choi, H. K., Liu, S., and Curhan, G.
(2005). Intake of purine-rich foods,
protein,anddairyproductsandrela-
tionship to serum levels of uric
acid: the Third National Health
and Nutrition Examination Survey.
Arthritis Rheum. 52, 283–289.
Chow, C. K. (1991). Vitamin E and
oxidative stress. Free Radic. Biol.
Med. 11, 215–232.
Church, W. H., and Ward, V. L. (1994).
Uricacidisreducedinthesubstantia
nigrainParkinson’sdisease:effecton
dopamineoxidation.BrainRes.Bull.
33, 419–425.
Cleren, C., Yang, L., Lorenzo, B., Calin-
gasan, N. Y., Schomer, A., Sireci,
A., Wille, E. J., and Beal, M. F.
(2008). Therapeutic effects of coen-
zyme Q10 (CoQ10) and reduced
CoQ10 in the MPTP model of
Parkinsonism. J. Neurochem. 104,
1613–1621.
Coimbra, C. G., and Junqueira, V. B.
(2003). High doses of riboﬂavin
and the elimination of dietary red
meat promote the recovery of some
motor functions in Parkinson’s dis-
ease patients. Braz. J. Med. Biol. Res.
36, 1409–1417.
Costa, G., Abin-Carriquiry, J. A., and
Dajas, F. (2001). Nicotine prevents
striatal dopamine loss produced by
6-hydroxydopamine lesion in the
substantia nigra. Brain Res. 888,
336–342.
Costa, J., Lunet, N., Santos, C., San-
tos, J., and Vaz-Carneiro, A. (2010).
Caffeine exposure and the risk of
Parkinson’s disease: a systematic
review and meta-analysis of obser-
vational studies. J. Alzheimers Dis.
20(Suppl. 1), S221–S238.
da Silva, T. M., Munhoz, R. P., Alvarez,
C., Naliwaiko, K., Kiss, A., Andrea-
tini, R., and Ferraz, A. C. (2008).
Depression in Parkinson’s disease: a
double-blind,randomized,placebo-
controlled pilot study of omega-3
fatty-acidsupplementation.J.Affect.
Disord. 111, 351–359.
Davies,K. J.,Sevanian,A.,Muakkassah-
Kelly,S. F.,and Hochstein,P. (1986).
Uric acid-iron ion complexes. A
new aspect of the antioxidant func-
tions of uric acid. Biochem. J. 235,
747–754.
de Lau, L. M., Koudstaal, P. J., Hof-
man,A.,and Breteler,M. M. (2005).
Serumuricacidlevelsandtheriskof
Parkinson disease. Ann. Neurol. 58,
797–800.
de Urquiza, A. M., Liu, S., Sjoberg, M.,
Zetterstrom,R.H.,Grifﬁths,W.,Sjo-
vall, J., and Perlmann, T. (2000).
Docosahexaenoic acid, a ligand for
the retinoid X receptor in mouse
brain. Science 290, 2140–2144.
Dedeoglu, A., Kubilus, J. K., Yang, L.,
Ferrante, K. L., Hersch, S. M., Beal,
M. F., and Ferrante, R. J. (2003).
Creatine therapy provides neuro-
protection after onset of clinical
symptoms in Huntington’s disease
transgenic mice. J. Neurochem. 85,
1359–1367.
Dexter, D. T., Ward, R. J., Wells, F. R.,
Daniel, S. E., Lees, A. J., Peters, T.
J., Jenner, P., and Marsden, C. D.
(1992). Alpha-tocopherol levels in
brain are not altered in Parkinson’s
disease. Ann. Neurol. 32, 591–593.
Di Matteo, V., Pierucci, M., Di Gio-
vanni, G., Di Santo, A., Poggi, A.,
Benigno,A.,and Esposito,E. (2006).
Aspirin protects striatal dopamin-
ergic neurons from neurotoxin-
induced degeneration: an in vivo
microdialysis study. Brain Res. 1095,
167–177.
Di Monte, D. A. (1991). Mitochondrial
DNA and Parkinson’s disease. Neu-
rology 41, 38–42; discussion 42–33.
Diguet, E., Fernagut, P. O., Wei, X., Du,
Y., Rouland, R., Gross, C., Bezard,
E., and Tison, F. (2004). Deleteri-
ous effects of minocycline in ani-
mal models of Parkinson’s disease
and Huntington’s disease. Eur. J.
Neurosci. 19, 3266–3276.
Dowling, G. A., Mastick, J., Colling,
E., Carter, J. H., Singer, C. M., and
Aminoff, M. J. (2005). Melatonin
for sleep disturbances in Parkinson’s
disease. Sleep Med. 6, 459–466.
Driver, J. A., Logroscino, G., Lu, L.,
Gaziano, J. M., and Kurth, T.
(2011). Use of non-steroidal anti-
inﬂammatory drugs and risk of
Parkinson’s disease: nested case-
control study. BMJ 342, d198.
www.frontiersin.org November 2011 | Volume 2 | Article 68 | 13Seidl and Potashkin Neuroprotection in Parkinson’s disease
Du, Y., Ma, Z., Lin, S., Dodel, R. C.,
Gao, F., Bales, K. R., Triarhou, L. C.,
Chernet, E., Perry, K. W., Nelson, D.
L., Luecke, S., Phebus, L. A., Bymas-
ter, F. P., and Paul, S. M. (2001).
Minocycline prevents nigrostriatal
dopaminergic neurodegeneration in
the MPTP model of Parkinson’s dis-
ease. Proc. Natl. Acad. Sci. U.S.A. 98,
14669–14674.
Duan, W., Ladenheim, B., Cutler, R. G.,
Kruman, II, Cadet, J. L., and Matt-
son, M. P. (2002). Dietary folate
deﬁciency and elevated homocys-
teine levels endanger dopaminergic
neurons in models of Parkinson’s
disease. J. Neurochem. 80, 101–110.
During,M.J.,Cao,L.,Zuzga,D.S.,Fran-
cis, J. S., Fitzsimons, H. L., Jiao, X.,
Bland, R. J., Klugmann, M., Banks,
W. A., Drucker, D. J., and Haile, C.
N. (2003). Glucagon-like peptide-
1 receptor is involved in learning
and neuroprotection. Nat. Med. 9,
1173–1179.
Ebadi, M., Sharma, S. K., Wanpen, S.,
and Amornpan, A. (2004). Coen-
zyme Q10 inhibits mitochondr-
ial complex-1 down-regulation and
nuclear factor-kappa B activation. J.
C e l l .M o l .M e d .8, 213–222.
Esposito, E., Di Matteo, V., Benigno,
A., Pierucci, M., Crescimanno, G.,
and Di Giovanni, G. (2007). Non-
steroidalanti-inﬂammatorydrugsin
Parkinson’sdisease.Exp.Neurol.205,
295–312.
Etminan, M., Gill, S. S., and Samii, A.
(2005). Intake of vitamin E,vitamin
C, and carotenoids and the risk of
Parkinson’s disease: a meta-analysis.
Lancet Neurol. 4, 362–365.
Evans, R. M. (1988). The steroid and
thyroid hormone receptor super-
family. Science 240, 889–895.
Everse, J., and Coates, P. W. (2004). The
cytotoxicactivityof lactoperoxidase:
enhancementandinhibitionbyneu-
roactive compounds. Free Radic.
Biol. Med. 37, 839–849.
Eyles, D., Brown, J., Mackay-Sim, A.,
McGrath, J., and Feron, F. (2003).
Vitamin D3 and brain development.
Neuroscience 118, 641–653.
Eyles, D. W., Smith, S., Kinobe, R.,
Hewison, M., and McGrath, J. J.
(2005). Distribution of the vitamin
D receptor and 1 alpha-hydroxylase
inhumanbrain.J.Chem.Neuroanat.
29, 21–30.
Fahn, S. (1992). A pilot trial of high-
dosealpha-tocopherolandascorbate
in early Parkinson’s disease. Ann.
Neurol. 32(Suppl.), S128–S132.
Fariss, M. W., and Zhang, J. G. (2003).
Vitamin E therapy in Parkinson’s
disease. Toxicology 189, 129–146.
Faust, K., Gehrke, S., Yang, Y., Yang,
L., Beal, M. F., and Lu, B.
(2009). Neuroprotective effects of
compounds with antioxidant and
anti-inﬂammatory properties in a
Drosophila model of Parkinson’s
disease. BMC Neurosci. 10, 109.
doi:10.1186/1471-2202-10-109
Ferger, B., Spratt, C., Earl, C. D.,
Teismann, P., Oertel, W. H., and
Kuschinsky, K. (1998). Effects of
nicotine on hydroxyl free rad-
ical formation in vitro and on
MPTP-induced neurotoxicity
in vivo. Naunyn SchmiedebergsArch.
Pharmacol. 358, 351–359.
Fernandez-Calle,P.,Jimenez-Jimenez,F.
J., Molina, J. A., Cabrera-Valdivia,
F., Vazquez, A., Garcia Urra, D.,
Bermejo,F.,CruzMatallana,M.,and
Codoceo, R. (1993). Serum levels of
ascorbicacid(vitaminC)inpatients
with Parkinson’s disease. J. Neurol.
Sci. 118, 25–28.
Fernandez-Calle, P., Molina, J. A.,
Jimenez-Jimenez, F. J., Vazquez,
A., Pondal, M., Garcia-Ruiz, P. J.,
Urra, D. G., Domingo, J., and
Codoceo, R. (1992). Serum levels
of alpha-tocopherol (vitamin E) in
Parkinson’s disease. Neurology 42,
1064–1066.
Ferrea,S.,andWinterer,G.(2009).Neu-
roprotective and neurotoxic effects
of nicotine. Pharmacopsychiatry 42,
255–265.
Fertl, E., Auff, E., Doppelbauer, A.,
and Waldhauser, F. (1993). Circa-
dian secretion pattern of melatonin
in de novo parkinsonian patients:
evidence for phase-shifting proper-
tiesofl-dopa.J.NeuralTransm.Park.
Dis. Dement. Sect. 5, 227–234.
Fowler, J. S., Volkow, N. D., Wang, G.
J., Pappas, N., Logan, J., MacGregor,
R., Alexoff, D., Shea, C., Schlyer, D.,
Wolf,A. P.,Warner,D.,Zezulkova,I.,
and Cilento,R. (1996). Inhibition of
monoamine oxidase B in the brains
of smokers. Nature 379, 733–736.
Galpern, W. R., and Cudkowicz, M.
E. (2007). Coenzyme Q treat-
ment of neurodegenerative diseases
of aging. Mitochondrion 7(Suppl.),
S146–S153.
Gao, X., Chen, H., Choi, H. K.,
Curhan, G., Schwarzschild, M. A.,
and Ascherio,A. (2008). Diet, urate,
and Parkinson’s disease risk in men.
Am. J. Epidemiol. 167, 831–838.
Gao, X., Chen, H., Schwarzschild, M.
A., and Ascherio, A. (2011). Use
of ibuprofen and risk of Parkinson
disease. Neurology 76, 863–869.
Garcion,E.,Wion-Barbot,N.,Montero-
Menei, C. N., Berger, F., and Wion,
D. (2002). New clues about vita-
min D functions in the nervous sys-
tem. Trends Endocrinol. Metab. 13,
100–105.
Gardian, G.,Yang, L., Cleren, C., Calin-
gasan,N.Y.,Klivenyi,P.,andBeal,M.
F. (2004). Neuroprotective effects of
phenylbutyrate against MPTP neu-
rotoxicity. Neuromolecular Med. 5,
235–241.
Garrido, M., Tereshchenko, Y.,
Zhevtsova, Z., Taschenberger,
G., Bahr, M., and Kugler, S.
(2011). Glutathione depletion and
overproduction both initiate degen-
eration of nigral dopaminergic
neurons. Acta Neuropathol. 121,
475–485.
Gash, D. M., Zhang, Z., Ovadia, A.,
Cass, W. A., Yi, A., Simmerman, L.,
Russell, D., Martin, D., Lapchak, P.
A., Collins, F., Hoffer, B. J., and
Gerhardt, G. A. (1996). Functional
recovery in parkinsonian monkeys
treated with GDNF. Nature 380,
252–255.
Gill, S. S., Patel, N. K., Hotton, G. R.,
O’Sullivan, K., McCarter, R., Bun-
nage, M., Brooks, D. J., Svendsen,
C. N., and Heywood, P. (2003).
Direct brain infusion of glial cell
line-derived neurotrophic factor in
Parkinson disease. Nat. Med. 9,
589–595.
Glover, J. (1960). The conversion of
beta-caroteneintovitaminA.Vitam.
Horm. 18, 371–386.
Gong, L., Daigneault, E. A.,Acuff, R. V.,
and Kostrzewa, R. M. (1991). Vit-
amin E supplements fail to protect
mice from acute MPTP neurotoxic-
ity. Neuroreport 2, 544–546.
Gotz,M.E.,Gerstner,A.,Harth,R.,Dirr,
A., Janetzky, B., Kuhn, W., Riederer,
P., and Gerlach, M. (2000). Altered
redox state of platelet coenzyme
Q10 in Parkinson’s disease. J. Neural
Transm. 107, 41–48.
Green, K. N., Martinez-Coria, H.,
Khashwji, H., Hall, E. B., Yurko-
Mauro,K.A.,Ellis,L.,andLaFerla,F.
M.(2007).Dietarydocosahexaenoic
acid and docosapentaenoic acid
ameliorate amyloid-beta and tau
pathology via a mechanism involv-
ingpresenilin1levels.J.Neurosci.27,
4385–4395.
Grunewald, R. A. (1993). Ascorbic acid
in the brain. Brain Res. Brain Res.
Rev. 18, 123–133.
Hargreaves, I. P., Lane,A., and Sleiman,
P. M. (2008). The coenzyme Q10
statusof thebrainregionsof Parkin-
son’s disease patients. Neurosci. Lett.
447, 17–19.
Harkavyi, A., Abuirmeileh, A., Lever,
R., Kingsbury, A. E., Biggs, C. S.,
andWhitton,P.S.(2008).Glucagon-
like peptide 1 receptor stimula-
tion reverses key deﬁcits in distinct
rodent models of Parkinson’s dis-
ease. J. Neuroinﬂammation 5, 19.
Harkavyi,A., and Whitton, P. S. (2010).
Glucagon-like peptide 1 receptor
stimulation as a means of neuro-
protection. Br. J. Pharmacol. 159,
495–501.
Hashimoto, M., Hossain, S., Shimada,
T., Sugioka, K., Yamasaki, H., Fujii,
Y.,Ishibashi,Y.,Oka,J.,andShido,O.
(2002). Docosahexaenoic acid pro-
videsprotectionfromimpairmentof
learning ability in Alzheimer’s dis-
ease model rats. J. Neurochem. 81,
1084–1091.
Hashimoto, M., Tanabe, Y., Fujii, Y.,
Kikuta, T., Shibata, H., and Shido,
O. (2005). Chronic administration
of docosahexaenoic acid amelio-
rates the impairment of spatial
cognition learning ability in amy-
loid beta-infused rats. J. Nutr. 135,
549–555.
Hauser, R. A., Lew, M. F., Hurtig,
H. I., Ondo, W. G., Wojcieszek,
J., and Fitzer-Attas, C. J. (2009).
Long-term outcome of early versus
delayed rasagiline treatment in early
Parkinson’s disease. Mov. Disord. 24,
564–573.
Heales, S. J., Menzes, A., and Davey,
G. P. (2011). Depletion of glu-
tathione does not affect electron
transport chain complex activity
in brain mitochondria: implications
for Parkinson disease and post-
mortem studies. Free Radic. Biol.
Med. 50, 899–902.
Heikkila, R. E., Manzino, L., Cab-
bat, F. S., and Duvoisin, R. C.
(1985). Studies on the oxidation of
the dopaminergic neurotoxin
1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine by monoamine
oxidase B. J. Neurochem. 45,
1049–1054.
Hernan,M.A.,Logroscino,G.,andGar-
cia Rodriguez, L. A. (2006). Non-
steroidal anti-inﬂammatory drugs
and the incidence of Parkinson dis-
ease. Neurology 66, 1097–1099.
Hink, H. U., Santanam, N., Dikalov,
S., McCann, L., Nguyen, A. D.,
Parthasarathy, S., Harrison, D. G.,
and Fukai, T. (2002). Peroxidase
properties of extracellular superox-
ide dismutase: role of uric acid in
modulating in vivo activity. Arte-
rioscler. Thromb. Vasc. Biol. 22,
1402–1408.
Hirsch, E. C., and Hunot, S. (2009).
Neuroinﬂammation in Parkinson’s
disease:atargetforneuroprotection?
Lancet Neurol. 8, 382–397.
Holick, M. F. (2007). Vitamin D deﬁ-
ciency.N.Engl.J.Med.357,266–281.
Holmes, A. D., Copland, D. A., Sil-
burn, P. A., and Chenery, H. J.
(2011). Acute nicotine enhances
strategy-based semantic processing
in Parkinson’s disease. Int. J. Neu-
ropsychopharmacol. 14, 877–885.
Holst,J. J.,Burcelin,R.,and Nathanson,
E. (2011). Neuroprotective proper-
ties of GLP-1: theoretical and prac-
tical applications. C u r r .M e d .R e s .
Opin. 27, 547–558.
Frontiers in Neurology | Neuropharmacology November 2011 | Volume 2 | Article 68 | 14Seidl and Potashkin Neuroprotection in Parkinson’s disease
Horrocks, L. A., and Yeo, Y. K. (1999).
Health beneﬁts of docosahexaenoic
acid (DHA). Pharmacol. Res. 40,
211–225.
Huang, W., Chen, Y., Shohami, E., and
Weinstock, M. (1999). Neuropro-
tective effect of rasagiline, a selec-
tivemonoamineoxidase-Binhibitor,
against closed head injury in the
mouse. Eur. J. Pharmacol. 366,
127–135.
Huennekens, F. M. (1956). Flavin
nucleotides and ﬂavoproteins. Expe-
rientia 12, 1–6.
Ibanez, P., De Michele, G., Bonifati,
V., Lohmann, E., Thobois, S., Pol-
lak, P., Agid, Y., Heutink, P., Durr,
A., and Brice, A. (2003). Screening
for DJ-1 mutations in early onset
autosomal recessive parkinsonism.
Neurology 61, 1429–1431.
Iida, M., Miyazaki, I., Tanaka, K., Kab-
uto, H., Iwata-Ichikawa, E., and
Ogawa, N. (1999). Dopamine D2
receptor-mediated antioxidant and
neuroprotectiveeffectsofropinirole,
a dopamine agonist. Brain Res. 838,
51–59.
Ilijic, E., Guzman, J. N., and Surmeier,
D. J. (2011). The L-type channel
antagonist isradipine is neuropro-
tective in a mouse model of Parkin-
son’s disease. Neurobiol. Dis. 43,
364–371.
Inden, M., Kitamura, Y., Takeuchi, H.,
Yanagida, T., Takata, K., Kobayashi,
Y., Taniguchi, T., Yoshimoto, K.,
Kaneko, M., Okuma, Y., Taira,
T., Ariga, H., and Shimohama,
S. (2007). Neurodegeneration of
mouse nigrostriatal dopaminergic
system induced by repeated oral
administration of rotenone is pre-
ventedby4-phenylbutyrate,achem-
ical chaperone. J. Neurochem. 101,
1491–1504.
Investigators, N. N.-P. (2006). A ran-
domized, double-blind, futility clin-
icaltrialof creatineandminocycline
inearlyParkinsondisease.Neurology
66, 664–671.
Investigators, N. N.-P. (2007). A ran-
domized clinical trial of coenzyme
Q10 and GPI-1485 in early Parkin-
son disease. Neurology 68, 20–28.
Investigators, N. N.-P. (2008). A pilot
clinicaltrialof creatineandminocy-
cline in early Parkinson disease: 18-
month results. Clin. Neuropharma-
col. 31, 141–150.
Jeerakathil, T., Johnson, J. A., Simpson,
S. H., and Majumdar, S. R. (2007).
Short-term risk for stroke is dou-
bled in persons with newly treated
type 2 diabetes compared with per-
sonswithoutdiabetes:apopulation-
based cohort study. Stroke 38,
1739–1743.
Jenner, P. (2003). Oxidative stress in
Parkinson’s disease. Ann. Neurol.
53(Suppl. 3), S26–S36; discussion
S36–S28.
Jenner, P., Schapira, A. H., and Mars-
den, C. D. (1992). New insights
intothecauseof Parkinson’sdisease.
Neurology 42, 2241–2250.
Jimenez-Jimenez, F. J., Molina, J. A.,
Fernandez-Calle, P., Vazquez, A.,
Cabrera-Valdivia, F., Catalan, M. J.,
Garcia-Albea, E., Bermejo, F., and
Codoceo, R. (1993). Serum levels of
beta-carotene and other carotenoids
inParkinson’sdisease.Neurosci.Lett.
157, 103–106.
Joghataie, M. T., Roghani, M., Negah-
dar, F., and Hashemi, L. (2004).
Protective effect of caffeine against
neurodegeneration in a model of
Parkinson’sdiseaseinrat:behavioral
and histochemical evidence. Parkin-
sonism Relat. Disord. 10, 465–468.
Jones,D. C.,Gunasekar,P. G.,Borowitz,
J. L., and Isom, G. E. (2000).
Dopamine-induced apoptosis is
mediated by oxidative stress and is
enhanced by cyanide in differenti-
ated PC12 cells. J. Neurochem. 74,
2296–2304.
Jump, D. B. (2002). Dietary polyun-
saturated fatty acids and regulation
of gene transcription. Curr. Opin.
Lipidol. 13, 155–164.
Kachroo, A., Irizarry, M. C., and
Schwarzschild, M. A. (2010). Caf-
feine protects against combined
paraquat and maneb-induced
dopaminergic neuron degeneration.
Exp. Neurol. 223, 657–661.
Kaempf-Rotzoll, D. E., Traber, M. G.,
and Arai, H. (2003). Vitamin E and
transfer proteins. Curr. Opin. Lipi-
dol. 14, 249–254.
Kartha, V. N., and Krishnamurthy, S.
(1977). Antioxidant function of vit-
amin A. Int. J. Vitam. Nutr. Res. 47,
394–401.
Kaufmann, W. E., Andreasson, K.
I., Isakson, P. C., and Wor-
ley, P. F. (1997). Cyclooxygenases
and the central nervous system.
Prostaglandins 54, 601–624.
Khaldy, H., Escames, G., Leon, J.,
Vives, F., Luna, J. D., and Acuna-
Castroviejo, D. (2000). Compara-
tiveeffectsof melatonin,L-deprenyl,
Trolox and ascorbate in the sup-
pression of hydroxyl radical forma-
tion during dopamine autoxidation
in vitro. J. Pineal Res. 29, 100–107.
Kim,H.Y. (2007). Novel metabolism of
docosahexaenoicacidinneuralcells.
J. Biol. Chem. 282, 18661–18665.
Kim, S., Moon, M., and Park, S. (2009).
Exendin-4 protects dopamin-
ergic neurons by inhibition of
microglial activation and matrix
metalloproteinase-3 expression in
an animal model of Parkinson’s
disease. J. Endocrinol. 202, 431–439.
Kim, Y. S., Joo, W. S., Jin, B. K., Cho,
Y. H., Baik, H. H., and Park, C.
W. (1998). Melatonin protects 6-
OHDA-induced neuronal death of
nigrostriatal dopaminergic system.
Neuroreport 9, 2387–2390.
Klivenyi, P., Andreassen, O. A., Fer-
rante, R. J., Dedeoglu, A., Mueller,
G., Lancelot, E., Bogdanov, M.,
Andersen, J. K., Jiang, D., and
Beal, M. F. (2000). Mice deﬁcient
in cellular glutathione peroxidase
show increased vulnerability to
malonate, 3-nitropropionic acid,
and 1-methyl-4-phenyl-1,2,5,6-
tetrahydropyridine. J. Neurosci. 20,
1–7.
Kordower, J. H., Emborg, M. E., Bloch,
J., Ma, S. Y., Chu, Y., Leventhal,
L., McBride, J., Chen, E. Y., Palﬁ,
S., Roitberg, B. Z., Brown, W. D.,
Holden, J. E., Pyzalski, R., Taylor,
M. D., Carvey, P., Ling, Z., Trono,
D., Hantraye, P., Deglon, N., and
Aebischer, P. (2000). Neurodegener-
ation prevented by lentiviral vector
deliveryof GDNFinprimatemodels
of Parkinson’s disease. Science 290,
767–773.
Kumar, C., Igbaria, A., D’Autreaux, B.,
Planson, A. G., Junot, C., Godat, E.,
Bachhawat,A.K.,Delaunay-Moisan,
A.,and Toledano,M. B. (2011). Glu-
tathione revisited:a vital function in
iron metabolism and ancillary role
in thiol-redox control. EMBO J. 30,
2044–2056.
Kupsch, A., Gerlach, M., Pupeter, S.
C., Sautter, J., Dirr, A., Arnold, G.,
Opitz, W., Przuntek, H., Riederer,
P., and Oertel, W. H. (1995). Pre-
treatment with nimodipine pre-
vents MPTP-induced neurotoxicity
at the nigral, but not at the stri-
atal level in mice. Neuroreport 6,
621–625.
Kupsch, A., Sautter, J., Gotz, M.
E., Breithaupt, W., Schwarz, J.,
Youdim, M. B., Riederer, P., Ger-
lach, M., and Oertel, W. H. (2001).
Monoamine oxidase-inhibition and
MPTP-induced neurotoxicity in the
non-human primate: comparison
of rasagiline (TVP 1012) with
selegiline. J. Neural Transm. 108,
985–1009.
Kupsch, A., Sautter, J., Schwarz, J.,
Riederer,P.,Gerlach,M.,and Oertel,
W. H. (1996). 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyridine-induced
neurotoxicity in non-human
primates is antagonized by pretreat-
ment with nimodipine at the nigral,
but not at the striatal level. Brain
Res. 741, 185–196.
Lan, J., and Jiang, D. H. (1997). Des-
ferrioxamine and vitamin E pro-
tectagainstironandMPTP-induced
neurodegenerationinmice.J.Neural
Transm. 104, 469–481.
Lang, A. E., and Lozano, A. M.
(1998). Parkinson’s disease. First of
two parts. N .E n g l .J .M e d .339,
1044–1053.
Langston, J. W. (1998). Epidemiology
versus genetics in Parkinson’s dis-
ease:progressinresolvinganage-old
debate. Ann. Neurol. 44, S45–S52.
Lawler, J. M., Barnes, W. S., Wu, G.,
Song, W., and Demaree, S. (2002).
Direct antioxidant properties of cre-
atine. Biochem. Biophys. Res. Com-
mun. 290, 47–52.
Lazaroff, M., Patankar, S., Yoon, S.
O., and Chikaraishi, D. M. (1995).
The cyclic AMP response element
directs tyrosine hydroxylase expres-
sion in catecholaminergic central
and peripheral nervous system cell
lines from transgenic mice. J. Biol.
Chem. 270, 21579–21589.
LeWitt, P. A. (1994). Clinical tri-
als of neuroprotection in Parkin-
son’s disease: long-term selegiline
and alpha-tocopherol treatment. J.
Neural Transm. Suppl. 43, 171–181.
Li,Y., Liu, L., Barger, S. W., Mrak, R. E.,
and Grifﬁn,W. S. (2001). Vitamin E
suppression of microglial activation
is neuroprotective. J. Neurosci. Res.
66, 163–170.
Li, Y., Perry, T., Kindy, M. S., Har-
vey, B. K., Tweedie, D., Holloway,
H. W., Powers, K., Shen, H., Egan,
J. M., Sambamurti, K., Brossi, A.,
Lahiri, D. K., Mattson, M. P., Hof-
fer, B. J., Wang, Y., and Greig, N.
H. (2009). GLP-1 receptor stimula-
tion preserves primary cortical and
dopaminergic neurons in cellular
and rodent models of stroke and
Parkinsonism. Proc. Natl. Acad. Sci.
U.S.A. 106, 1285–1290.
Lim,G. P.,Calon,F.,Morihara,T.,Yang,
F., Teter, B., Ubeda, O., Salem, N.
Jr., Frautschy, S. A., and Cole, G.
M. (2005). A diet enriched with the
omega-3 fatty acid docosahexaenoic
acid reduces amyloid burden in an
aged Alzheimer mouse model. J.
Neurosci. 25, 3032–3040.
Linville,D.G.,Williams,S.,Raszkiewicz,
J. L.,and Arneric,S. P. (1993). Nico-
tinic agonists modulate basal fore-
brain control of cortical cerebral
blood ﬂow in anesthetized rats. J.
Pharmacol. Exp. Ther. 267, 440–448.
Logroscino,G.,Marder,K.,Graziano,J.,
Freyer, G., Slavkovich, V., LoIacono,
N., Cote, L., and Mayeux, R. (1997).
Altered systemic iron metabolism in
Parkinson’s disease. Neurology 49,
714–717.
www.frontiersin.org November 2011 | Volume 2 | Article 68 | 15Seidl and Potashkin Neuroprotection in Parkinson’s disease
Maggio, R., Riva, M., Vaglini, F., For-
nai, F., Racagni, G., and Corsini, G.
U. (1997). Striatal increase of neu-
rotrophic factors as a mechanism of
nicotine protection in experimental
parkinsonism.J.NeuralTransm.104,
1113–1123.
Maharaj, D. S., Maharaj, H., Daya, S.,
and Glass, B. D. (2006a). Mela-
tonin and 6-hydroxymelatonin pro-
tect against iron-induced neurotox-
icity. J. Neurochem. 96, 78–81.
Maharaj, H., Maharaj, D. S., and
Daya, S. (2006b). Acetylsalicylic
acid and acetaminophen protect
against MPP+-induced mitochon-
drial damage and superoxide anion
generation. Life Sci. 78, 2438–2443.
Martin, H. L., and Teismann, P. (2009).
Glutathione–areviewonitsroleand
signiﬁcance in Parkinson’s disease.
FASEB J. 23, 3263–3272.
Martin, V., Sainz, R. M., Antolin,
I., Mayo, J. C., Herrera, F., and
Rodriguez, C. (2002). Several
antioxidantpathwaysareinvolvedin
astrocyte protection by melatonin.
J. Pineal Res. 33, 204–212.
Maruyama, W., Akao, Y., Youdim,
M. B., and Naoi, M. (2000).
Neurotoxins induce apoptosis in
dopamine neurons: protection by
N-propargylamine-1(R)- and (S)-
aminoindan,rasagilineandTV1022.
J.NeuralTransm.Suppl.60,171–186.
Massaro, M., Habib, A., Lubrano, L.,
DelTurco,S.,Lazzerini,G.,Bourcier,
T., Weksler, B. B., and De Cate-
rina, R. (2006). The omega-3 fatty
acid docosahexaenoate attenuates
endothelialcyclooxygenase-2induc-
tion through both NADP(H) oxi-
dase and PKC epsilon inhibition.
Proc. Natl. Acad. Sci. U.S.A. 103,
15184–15189.
Matsubara, T., Azums, T., Yoshids, S.,
and Yamegami, T. (1991). Biomed-
ical and Clinical Aspects of Coen-
zymeQ,Vol.16.Amsterdam:Elsevier
Science, 159–166.
Matthews,R.T.,Ferrante,R.J.,Klivenyi,
P.,Yang,L.,Klein,A. M.,Mueller,G.,
Kaddurah-Daouk, R., and Beal, M.
F.(1999).Creatineandcyclocreatine
attenuate MPTP neurotoxicity. Exp.
Neurol. 157, 142–149.
Mayo, J. C., Sainz, R. M., Antolin, I.,
and Rodriguez, C. (1999). Ultra-
structural conﬁrmation of neuronal
protection by melatonin against the
neurotoxin 6-hydroxydopamine cell
damage. Brain Res. 818, 221–227.
Mayo, J. C., Sainz, R. M., Tan, D. X.,
Antolin,I.,Rodriguez,C.,andReiter,
R. J. (2005). Melatonin and Parkin-
son’sdisease.Endocrine 27,169–178.
Mayo, J. C., Sainz, R. M., Uria, H.,
Antolin, I., Esteban, M. M., and
Rodriguez, C. (1998). Melatonin
prevents apoptosis induced by 6-
hydroxydopamine in neuronal cells:
implications for Parkinson’s disease.
J. Pineal Res. 24, 179–192.
McClean, P. L., Parthsarathy, V., Faivre,
E., and Holscher, C. (2010). The
novel GLP-1 analogue liraglutide
has neuroprotective properties in a
mousemodelofAlzheimer’sdisease.
Regul. Pept. 164, 40.
McClean, P. L., Parthsarathy, V., Faivre,
E., and Holscher, C. (2011). The
diabetes drug liraglutide prevents
degenerative processes in a mouse
modelofAlzheimer’sdisease.J.Neu-
rosci. 31, 6587–6594.
Merrill, A. H. Jr., Lambeth, J. D.,
Edmondson,D. E.,and McCormick,
D. B. (1981). Formation and mode
ofactionofﬂavoproteins.Annu.Rev.
Nutr. 1, 281–317.
Meshul,C.K.,Kamel,D.,Moore,C.,Kay,
T. S., and Krentz, L. (2002). Nico-
tinealtersstriatalglutamatefunction
and decreases the apomorphine-
induced contralateral rotations in 6-
OHDA-lesioned rats. Exp. Neurol.
175, 257–274.
Michel, P. P., Hirsch, E. C., and
Agid, Y. (2002). Parkinson’s disease:
cell death mechanisms. Rev. Neurol.
(Paris) 158, 24–32.
Miller, J. W., Selhub, J., and Joseph, J.
A. (1996). Oxidative damage caused
byfreeradicalsproducedduringcat-
echolamine autoxidation: protective
effects of O-methylation and mela-
tonin. Free Radic. Biol. Med. 21,
241–249.
Molina, J. A., de Bustos, F., Jimenez-
Jimenez, F. J., Benito-Leon, J., Orti-
Pareja, M., Gasalla, T., Tallon-
Barranco, A., Navarro, J. A., Are-
nas, J., and Enriquez-de-Salamanca,
R. (1997). Cerebrospinal ﬂuid lev-
els of alpha-tocopherol (vitamin E)
in Parkinson’s disease. J. Neural
Transm. 104, 1287–1293.
Morens,D.M.,Grandinetti,A.,Waslien,
C. I., Park, C. B., Ross, G. W., and
White, L. R. (1996). Case-control
study of idiopathic Parkinson’s dis-
ease and dietary vitamin E intake.
Neurology 46, 1270–1274.
Morioka, N., Kumagai, K., Morita,
K., Kitayama, S., and Dohi,
T. (2004). Nonsteroidal anti-
inﬂammatory drugs potentiate
1-methyl-4-phenylpyridinium
(MPP+)-induced cell death by
promoting the intracellular accu-
mulation of MPP+ in PC12 cells. J.
Pharmacol. Exp. Ther. 310, 800–807.
Murakami, K., Miyake, Y., Sasaki, S.,
Tanaka, K., Fukushima, W., Kiy-
ohara, C., Tsuboi, Y., Yamada, T.,
Oeda, T., Miki, T., Kawamura, N.,
Sakae, N., Fukuyama, H., Hirota, Y.,
andNagai,M.(2010).Dietaryintake
of folate, vitamin B6, vitamin B12
and riboﬂavin and risk of Parkin-
son’s disease: a case-control study in
Japan. B r .J .N u t r .104, 757–764.
Murer, M. G., Yan, Q., and Raisman-
Vozari, R. (2001). Brain-derived
neurotrophic factor in the control
human brain, and in Alzheimer’s
disease and Parkinson’s disease.
Prog. Neurobiol. 63, 71–124.
Nakaso, K., Ito, S., and Nakashima,
K. (2008). Caffeine activates the
PI3K/Akt pathway and prevents
apoptotic cell death in a Parkinson’s
disease model of SH-SY5Y cells.
Neurosci. Lett. 432, 146–150.
Naveilhan, P., Neveu, I., Wion, D.,
and Brachet, P. (1996). 1,25-
DihydroxyvitaminD3,aninducerof
glial cell line-derived neurotrophic
factor. Neuroreport 7, 2171–2175.
NET-PD, N. (2006). A randomized,
double-blind, futility clinical trial of
creatine and minocycline in early
Parkinson disease. Neurology 66,
664–671.
Obata,T. (2003). Phytic acid suppresses
1-methyl-4-phenylpyridinium ion-
induced hydroxyl radical genera-
tion in rat striatum. Brain Res. 978,
241–244.
Odunze, I. N., Klaidman, L. K., and
Adams, J. D. Jr. (1990). MPTP tox-
icityinthemousebrainandvitamin
E. Neurosci. Lett. 108, 346–349.
Offen, D., Ziv, I., Sternin, H., Melamed,
E.,andHochman,A.(1996).Preven-
tionof dopamine-inducedcelldeath
bythiolantioxidants:possibleimpli-
cations for treatment of Parkinson’s
disease. Exp. Neurol. 141, 32–39.
Olanow, C. W., Rascol, O., Hauser, R.,
Feigin, P. D., Jankovic, J., Lang, A.,
Langston, W., Melamed, E., Poewe,
W.,Stocchi,F.,andTolosa,E.(2009).
Adouble-blind,delayed-starttrialof
rasagiline in Parkinson’s disease. N.
E n g l .J .M e d .361, 1268–1278.
Ozsoy, O., Seval-Celik, Y., Hacioglu, G.,
Yargicoglu, P., Demir, R., Agar, A.,
and Aslan, M. (2011). The inﬂu-
ence and the mechanism of docosa-
hexaenoic acid on a mouse model of
Parkinson’s disease. Neurochem. Int.
59, 664–670.
Palacios, N., Weisskopf, M., Simon,
K., Gao, X., Schwarzschild, M., and
Ascherio,A. (2010). Polymorphisms
of caffeine metabolism and estro-
gen receptor genes and risk of
Parkinson’s disease in men and
women. Parkinsonism Relat. Disord.
16, 370–375.
Paraskevas, G. P., Kapaki, E.,
Petropoulou, O., Anagnostouli,
M., Vagenas, V., and Papageorgiou,
C. (2003). Plasma levels of antioxi-
dant vitamins C and E are decreased
in vascular parkinsonism. J. Neurol.
Sci. 215, 51–55.
Pearce, R. K., Owen, A., Daniel, S., Jen-
ner, P., and Marsden, C. D. (1997).
Alterations in the distribution of
glutathione in the substantia nigra
in Parkinson’s disease. J. Neural
Transm. 104, 661–677.
Perlmutter, J. S. (1988). New insights
into the pathophysiology of Parkin-
son’s disease: the challenge of
positron emission tomography.
Trends Neurosci. 11, 203–208.
Perry, T., and Greig, N. H. (2005).
Enhancing central nervous system
endogenous GLP-1 receptor path-
ways for intervention in Alzheimer’s
disease. Curr. Alzheimer Res. 2,
377–385.
Perry,T.,Holloway,H. W.,Weerasuriya,
A., Mouton, P. R., Duffy, K., Matti-
son, J. A., and Greig, N. H. (2007).
Evidenceof GLP-1-mediatedneuro-
protection in an animal model of
pyridoxine-induced peripheral sen-
sory neuropathy. Exp. Neurol. 203,
293–301.
Perry, T., Lahiri, D. K., Chen, D., Zhou,
J.,Shaw,K.T.,Egan,J.M.,andGreig,
N. H. (2002). A novel neurotrophic
property of glucagon-like peptide 1:
ap r o m o t e ro fn e r v eg r o w t hf a c t o r -
mediated differentiation in PC12
cells. J. Pharmacol. Exp. Ther. 300,
958–966.
Perry, T. L., Godin, D. V., and Hansen,
S. (1982). Parkinson’s disease: a
disorder due to nigral glutathione
deﬁciency? Neurosci. Lett. 33,
305–310.
Perry, T. L., Yong, V. W., Clavier, R. M.,
Jones, K., Wright, J. M., Foulks, J.
G., and Wall, R. A. (1985). Partial
protection from the dopaminergic
neurotoxin N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine by
four different antioxidants in
the mouse. Neurosci. Lett. 60,
109–114.
Perry, T. L., Yong, V. W., Hansen, S.,
Jones, K., Bergeron, C., Foulks, J. G.,
and Wright, J. M. (1987). Alpha-
tocopherol and beta-carotene do
not protect marmosets against
the dopaminergic neurotoxicity
of N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine. J. Neurol. Sci.
81, 321–331.
Frontiers in Neurology | Neuropharmacology November 2011 | Volume 2 | Article 68 | 16Seidl and Potashkin Neuroprotection in Parkinson’s disease
Pileblad, E., Magnusson, T., and
Fornstedt, B. (1989). Reduc-
tion of brain glutathione by
L-buthionine sulfoximine poten-
tiates the dopamine-depleting
action of 6-hydroxydopamine in rat
striatum.J.Neurochem.52,978–980.
Pizzi, M., Ribola, M., Valerio, A.,
Memo, M., and Spano, P. (1991).
Various Ca2+ entry blockers pre-
vent glutamate-induced neurotoxic-
ity. Eur. J. Pharmacol. 209, 169–173.
Powers, H. J. (1987). A study of
maternofetal iron transfer in the
riboﬂavin-deﬁcient rat. J. Nutr. 117,
852–856.
Powers, H. J. (2003). Riboﬂavin (vita-
min B-2) and health. Am. J. Clin.
Nutr. 77, 1352–1360.
Powers,H.J.,Bates,C.J.,andDuerden,J.
M. (1983). Effects of riboﬂavin deﬁ-
ciencyinratsonsomeaspectsofiron
metabolism. Int. J. Vitam. Nutr. Res.
53, 371–376.
Prediger,R.D.(2010).Effectsofcaffeine
in Parkinson’s disease: from neuro-
protection to the management of
motor and non-motor symptoms. J.
Alzheimers Dis. 20(Suppl. 1), S205–
S220.
Quick, M. (2004). Smoking, nicotine
andParkinson’sdisease.TrendsNeu-
rosci. 27, 561–568.
Quik, M., and Jeyarasasingam, G.
(2000). Nicotinic receptors and
Parkinson’s disease. Eur. J. Pharma-
col. 393, 223–230.
Quik, M., Parameswaran, N., McCal-
lum, S. E., Bordia, T., Bao, S.,
McCormack, A., Kim, A., Tyndale,
R. F., Langston, J. W., and Di
Monte, D. A. (2006). Chronic oral
nicotine treatment protects against
striatal degeneration in MPTP-
treated primates. J. Neurochem. 98,
1866–1875.
Quintero, E. M., Willis, L., Single-
ton, R., Harris, N., Huang, P.,
Bhat, N., and Granholm, A. C.
(2006). Behavioral and morpholog-
ical effects of minocycline in the
6-hydroxydopamine rat model of
Parkinson’s disease. Brain Res. 1093,
198–207.
Radad, K., Moldzio, R., and Rausch,
W. D. (2010). Minocycline protects
dopaminergic neurons against long-
term rotenone toxicity. Can. J. Neu-
rol. Sci. 37, 81–85.
Rascol, O., Fitzer-Attas, C. J., Hauser,
R., Jankovic, J., Lang, A., Langston,
J. W., Melamed, E., Poewe, W., Stoc-
chi, F., Tolosa, E., Eyal, E., Weiss,
Y. M., and Olanow, C. W. (2011).
A double-blind, delayed-start trial
of rasagiline in Parkinson’s dis-
ease (the ADAGIO study): pre-
speciﬁed and post-hoc analyses of
the need for additional therapies,
changes in UPDRS scores, and non-
motor outcomes. Lancet Neurol. 10,
415–423.
Ravina, B. M., Fagan, S. C., Hart, R.
G., Hovinga, C. A., Murphy, D. D.,
Dawson, T. M., and Marler, J. R.
(2003). Neuroprotective agents for
clinicaltrialsinParkinson’sdisease:a
systematicassessment.Neurology 60,
1234–1240.
Reiter, R. J., Carneiro, R. C., and Oh,
C. S. (1997). Melatonin in rela-
tion to cellular antioxidative defense
mechanisms. Horm. Metab. Res. 29,
363–372.
Ren, Y. R., Nishida, Y., Yoshimi,
K., Yasuda, T., Jishage, K., Uchi-
hara, T., Yokota, T., Mizuno, Y.,
and Mochizuki, H. (2006). Genetic
vitamin E deﬁciency does not
affect MPTP susceptibility in the
mouse brain. J. Neurochem. 98,
1810–1816.
Ricciarelli,R.,Argellati,F.,Pronzato,M.
A., and Domenicotti, C. (2007).Vit-
amin E and neurodegenerative dis-
eases.Mol.AspectsMed.28,591–606.
Riederer, P., Soﬁc, E., Rausch, W.
D., Schmidt, B., Reynolds, G. P.,
Jellinger, K., and Youdim, M. B.
(1989). Transition metals, ferritin,
glutathione, and ascorbic acid in
parkinsonian brains. J. Neurochem.
52, 515–520.
Rocchitta, G., Migheli, R., Esposito, G.,
Marchetti, B., Desole, M. S., Miele,
E., and Serra, P. A. (2006). Endoge-
nous melatonin protects L-DOPA
from autoxidation in the striatal
extracellular compartment of the
freely moving rat: potential implica-
tion for long-term L-DOPA therapy
in Parkinson’s disease. J. Pineal Res.
40, 204–213.
Roghani, M., and Behzadi, G. (2001).
Neuroprotective effect of vitamin E
on the early model of Parkinson’s
disease in rat: behavioral and his-
tochemical evidence. Brain Res. 892,
211–217.
Ross, G. W., Abbott, R. D., Petrovitch,
H., Morens, D. M., Grandinetti,
A., Tung, K. H., Tanner, C. M.,
Masaki, K. H., Blanchette, P. L.,
Curb, J. D., Popper, J. S., and White,
L. R. (2000). Association of coffee
and caffeine intake with the risk
of Parkinson disease. JAMA 283,
2674–2679.
Ryan, M. E., and Ashley, R. A. (1998).
How do tetracyclines work? Adv.
Dent. Res. 12, 149–151.
Ryan, M. E., Ramamurthy, N. S., and
Golub, L. M. (1998). Tetracyclines
inhibit protein glycation in experi-
mental diabetes. Adv. Dent. Res. 12,
152–158.
Saaksjarvi, K., Knekt, P., Rissanen, H.,
Laaksonen, M. A., Reunanen, A.,
andMannisto,S.(2008).Prospective
study of coffee consumption and
risk of Parkinson’s disease. Eur. J.
Clin. Nutr. 62, 908–915.
Sagi,Y.,Weinreb,O.,Weinstock,M.,and
Youdim, M. B. (2001). Neuropro-
tective and neurorescue properties
of rasagiline and TV3326 in MPTP
modelof Parkinson’sdisease.Neural
Plast. 8, 197–198.
Saini, T., Bagchi, M., Bagchi, D., Jaeger,
S., Hosoyama, S., and Stohs, S. J.
(1998). Protective ability of acetyl-
salicylic acid (aspirin) to scavenge
radiation induced free radicals in
J774A.1 macrophage cells. Res Com-
mun. Mol. Pathol. Pharmacol. 101,
259–268.
Sairam, K., Saravanan, K. S., Banerjee,
R., and Mohanakumar, K. P. (2003).
Non-steroidal anti-inﬂammatory
drug sodium salicylate, but not
diclofenac or celecoxib, pro-
tects against 1-methyl-4-phenyl
pyridinium-induced dopaminergic
neurotoxicity in rats. Brain Res. 966,
245–252.
Sakamoto, T., Cansev, M., and Wurt-
man, R. J. (2007). Oral supplemen-
tation with docosahexaenoic acid
and uridine-5 -monophosphate
increases dendritic spine density in
adult gerbil hippocampus. Brain
Res. 1182, 50–59.
Salem, N. Jr., Litman, B., Kim, H. Y.,
and Gawrisch, K. (2001). Mecha-
nisms of action of docosahexaenoic
acidinthenervoussystem.Lipids 36,
945–959.
Samadi, P., Gregoire, L., Rouil-
lard, C., Bedard, P. J., Di Paolo,
T., and Levesque, D. (2006).
Docosahexaenoic acid reduces
levodopa-induced dyskinesias
in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine monkeys. Ann.
Neurol. 59, 282–288.
Samii, A., Etminan, M., Wiens, M. O.,
andJafari,S.(2009).NSAIDuseand
the risk of Parkinson’s disease: sys-
tematic review and meta-analysis of
observational studies. Drugs Aging
26, 769–779.
Sandyk, R. (1990). Mechanisms of
actionof ECTinParkinson’sdisease:
possible role of pineal melatonin.
Int. J. Neurosci. 50, 83–94.
Sato, Y., Kikuyama, M., and Oizumi, K.
(1997). High prevalence of vitamin
Ddeﬁciencyandreducedbonemass
inParkinson’sdisease.Neurology 49,
1273–1278.
Sautter, J., Kupsch, A., Earl, C. D.,
and Oertel, W. H. (1997). Degen-
eration of pre-labelled nigral neu-
rons induced by intrastriatal 6-
hydroxydopamine in the rat: behav-
ioural and biochemical changes and
pretreatmentwiththecalcium-entry
blocker nimodipine. Exp. Brain Res.
117, 111–119.
Scheider, W. L., Hershey, L. A., Vena, J.
E.,Holmlund,T.,Marshall,J.R.,and
Freudenheim, J. L. (1997). Dietary
antioxidants and other dietary fac-
tors in the etiology of Parkin-
son’s disease. Mov. Disord. 12,
190–196.
Scherzer, C. R., Eklund, A. C., Morse,
L. J., Liao, Z., Locascio, J. J., Fefer,
D., Schwarzschild, M. A., Schloss-
macher,M.G.,Hauser,M.A.,Vance,
J. M., Sudarsky, L. R., Standaert, D.
G., Growdon, J. H., Jensen, R. V.,
and Gullans, S. R. (2007). Molecu-
lar markers of early Parkinson’s dis-
ease based on gene expression in
blood. Proc. Natl. Acad. Sci. U.S.A.
104, 955–960.
Schlesinger, I., and Schlesinger, N.
(2008). Uric acid in Parkinson’s dis-
ease. Mov. Disord. 23, 1653–1657.
Schulz, J. B., Lindenau, J., Seyfried,
J., and Dichgans, J. (2000). Glu-
tathione, oxidative stress and neu-
rodegeneration.Eur.J.Biochem.267,
4904–4911.
Schwarzschild, M. A., Schwid, S. R.,
Marek, K., Watts, A., Lang, A. E.,
Oakes, D., Shoulson, I.,Ascherio,A.,
Hyson, C., Gorbold, E., Rudolph,
A., Kieburtz, K., Fahn, S., Gauger,
L., Goetz, C., Seibyl, J., Forrest,
M., and Ondrasik, J. (2008). Serum
urate as a predictor of clinical
and radiographic progression in
Parkinson disease. Arch. Neurol. 65,
716–723.
Seaton, T. A., Jenner, P., and Marsden,
C. D. (1996). Thioctic acid does
notrestoreglutathionelevelsorpro-
tect against the potentiation of 6-
hydroxydopamine toxicity induced
byglutathionedepletioninratbrain.
J. Neural Transm. 103, 315–329.
Shamsuddin, A. M., Vucenik, I., and
Cole, K. E. (1997). IP6: a novel
anti-cancer agent. Life Sci. 61,
343–354.
Sharma, S., Kheradpezhou, M., Shavali,
S., El Refaey, H., Eken, J., Hagen,
C.,andEbadi,M.(2004).Neuropro-
tective actions of coenzyme Q10 in
Parkinson’s disease. Meth. Enzymol.
382, 488–509.
Shults, C. W. (2003). Coenzyme Q10
in neurodegenerative diseases. Curr.
Med. Chem. 10, 1917–1921.
Shults, C. W., Flint Beal, M., Song, D.,
and Fontaine, D. (2004). Pilot trial
of high dosages of coenzyme Q10
in patients with Parkinson’s disease.
Exp. Neurol. 188, 491–494.
Shults,C.W.,Haas,R.H.,andBeal,M.F.
(1999). A possible role of coenzyme
Q10 in the etiology and treatment
of Parkinson’s disease. Biofactors 9,
267–272.
www.frontiersin.org November 2011 | Volume 2 | Article 68 | 17Seidl and Potashkin Neuroprotection in Parkinson’s disease
Shults,C.W.,Haas,R.H.,Passov,D.,and
Beal, M. F. (1997). Coenzyme Q10
levels correlate with the activities of
complexes I and II/III in mitochon-
dria from parkinsonian and non-
parkinsonian subjects. Ann. Neurol.
42, 261–264.
Shults, C. W., Oakes, D., Kieburtz, K.,
Beal, M. F., Haas, R., Plumb, S.,
Juncos, J. L., Nutt, J., Shoulson, I.,
Carter, J., Kompoliti, K., Perlmutter,
J. S., Reich, S., Stern, M., Watts, R.
L., Kurlan, R., Molho, E., Harrison,
M., and Lew, M. (2002). Effects of
coenzyme Q10 in early Parkinson
disease: evidence of slowing of the
functional decline. Arch. Neurol. 59,
1541–1550.
Sian, J., Dexter, D. T., Lees, A. J.,
Daniel, S., Agid, Y., Javoy-Agid, F.,
Jenner, P., and Marsden, C. D.
(1994). Alterations in glutathione
levels in Parkinson’s disease and
other neurodegenerative disorders
affecting basal ganglia. Ann. Neurol.
36, 348–355.
Simon, K. C., Chen, H., Gao, X.,
Schwarzschild, M. A., and Ascherio,
A. (2009). Reproductive factors,
exogenous estrogen use, and risk of
Parkinson’s disease. Mov. Disord. 24,
1359–1365.
Simuni, T., Borushko, E., Avram, M. J.,
Miskevics, S., Martel, A., Zadikoff,
C., Videnovic, A., Weaver, F. M.,
Williams, K., and Surmeier, D. J.
(2010). Tolerability of isradipine in
earlyParkinson’sdisease:apilotdose
escalation study. Mov. Disord. 25,
2863–2866.
Singh, S., Singh, K., Patel, S., Patel, D.
K., Singh, C., Nath, C., and Singh,
M. P. (2008). Nicotine and caffeine-
mediated modulation in the expres-
sionoftoxicantresponsivegenesand
vesicular monoamine transporter-
2 in 1-methyl 4-phenyl-1,2,3,6-
tetrahydropyridine-induced Parkin-
son’s disease phenotype in mouse.
Brain Res. 1207, 193–206.
Sirivech, S., Driskell, J., and Frieden,
E.(1977).NADH-FMNoxidoreduc-
tase activity and iron content of
organs from riboﬂavin and iron-
deﬁcient rats. J. Nutr. 107, 739–745.
Smith, M. P., Fletcher-Turner, A.,
Yurek, D. M., and Cass, W. A.
(2006). Calcitriol protection against
dopaminelossinducedbyintracere-
broventricular administration of 6-
hydroxydopamine. Neurochem. Res.
31, 533–539.
Sohmiya, M., Tanaka, M., Tak, N. W.,
Yanagisawa, M., Tanino, Y., Suzuki,
Y., Okamoto, K., and Yamamoto, Y.
(2004).Redoxstatusofplasmacoen-
zyme Q10 indicates elevated sys-
temic oxidative stress in Parkinson’s
disease. J. Neurol. Sci. 223, 161–166.
Speiser, Z., Mayk, A., Eliash, S., and
Cohen,S.(1999).Studieswithrasag-
iline, a MAO-B inhibitor, in experi-
mental focal ischemia in the rat. J.
Neural Transm. 106, 593–606.
Sriram, K., Miller, D. B., and
O’Callaghan, J. P. (2006). Minocy-
clineattenuatesmicroglialactivation
but fails to mitigate striatal
dopaminergic neurotoxicity: role
of tumor necrosis factor-alpha. J.
Neurochem. 96, 706–718.
Takeuchi, H., Yanagida, T., Inden, M.,
Takata, K., Kitamura, Y., Yamakawa,
K.,Sawada,H.,Izumi,Y.,Yamamoto,
N., Kihara, T., Uemura, K., Inoue,
H., Taniguchi, T., Akaike, A., Taka-
hashi,R.,andShimohama,S.(2009).
Nicotinic receptor stimulation pro-
tectsnigraldopaminergicneuronsin
rotenone-induced Parkinson’s dis-
ease models. J. Neurosci. Res. 87,
576–585.
Tan, E. K., Tan, C., Fook-Chong, S.
M., Lum, S. Y., Chai, A., Chung,
H., Shen, H., Zhao, Y., Teoh, M. L.,
Yih, Y., Pavanni, R., Chandran, V.
R., and Wong, M. C. (2003). Dose-
dependentprotectiveeffectofcoffee,
tea, and smoking in Parkinson’s dis-
ease: a study in ethnic Chinese. J.
Neurol. Sci. 216, 163–167.
Tapias, V., Cannon, J. R., and
Greenamyre, J. T. (2010). Melatonin
treatment potentiates neurodegen-
eration in a rat rotenone Parkinson’s
disease model. J. Neurosci. Res. 88,
420–427.
Tappel, A. (1962). Vitamin E as the
biological lipid antioxidant. Vitam.
Horm. 20, 493–509.
Tarnopolsky, M. A., and Beal, M. F.
(2001). Potential for creatine and
other therapies targeting cellular
energy dysfunction in neurological
disorders. Ann. Neurol. 49, 561–574.
Tatton, W., Chalmers-Redman, R.,
and Tatton, N. (2003). Neuro-
protection by deprenyl and other
propargylamines: glyceraldehyde-3-
phosphate dehydrogenase rather
than monoamine oxidase B. J.
Neural Transm. 110, 509–515.
Tikka, T., Fiebich, B. L., Goldsteins,
G., Keinanen, R., and Koistinaho, J.
(2001). Minocycline, a tetracycline
derivative,isneuroprotectiveagainst
excitotoxicity by inhibiting activa-
tion and proliferation of microglia.
J. Neurosci. 21, 2580–2588.
Tohgi, H., Abe, T., Takahashi, S., and
Kikuchi, T. (1993). The urate and
xanthine concentrations in the cere-
brospinal ﬂuid in patients with vas-
cular dementia of the Binswanger
type, Alzheimer type dementia,
and Parkinson’s disease. J. Neural
Transm. Park. Dis. Dement. Sect. 6,
119–126.
Ton, T. G., Heckbert, S. R., Longstreth,
W. T. Jr., Rossing, M. A., Kukull,
W. A., Franklin, G. M., Swanson,
P. D., Smith-Weller, T., and Check-
oway, H. (2006). Nonsteroidal anti-
inﬂammatory drugs and risk of
Parkinson’s disease. Mov. Disord. 21,
964–969.
Toulorge, D., Guerreiro, S., Hild, A.,
Maskos, U., Hirsch, E. C., and
Michel, P. P. (2011). Neuroprotec-
tion of midbrain dopamine neurons
by nicotine is gated by cytoplasmic
Ca2+. FASEB J. 25, 2563–2573.
Traber,M. G.,and Sies,H. (1996).Vita-
minEinhumans:demandanddeliv-
ery. A n n u .R e v .N u t r .16, 321–347.
Trinh,K.,Andrews,L.,Krause,J.,Hanak,
T., Lee, D., Gelb, M., and Pallanck,
L. (2010). Decaffeinated coffee and
nicotine-free tobacco provide neu-
roprotection in Drosophila mod-
els of Parkinson’s disease through
an NRF2-dependent mechanism. J.
Neurosci. 30, 5525–5532.
van den Pol, A. N. (1986). Tyrosine
hydroxylase immunoreactive neu-
rons throughout the hypothala-
mus receive glutamate decarboxy-
lase immunoreactive synapses: a
double pre-embedding immunocy-
tochemical study with particulate
silver and HRP. J. Neurosci. 6,
877–891.
Wahner, A. D., Bronstein, J. M., Borde-
lon,Y. M., and Ritz, B. (2007). Non-
steroidal anti-inﬂammatory drugs
may protect against Parkinson dis-
ease. Neurology 69, 1836–1842.
Wang, J. Y., Wu, J. N., Cherng, T.
L., Hoffer, B. J., Chen, H. H.,
Borlongan, C. V., and Wang, Y.
(2001). Vitamin D(3) attenuates 6-
hydroxydopamine-induced neuro-
toxicityinrats.BrainRes.904,67–75.
Wang, X., Zhao, X., Mao, Z. Y., Wang,
X. M., and Liu, Z. L. (2003). Neuro-
protective effect of docosahexaenoic
acid on glutamate-induced cytotox-
icity in rat hippocampal cultures.
Neuroreport 14, 2457–2461.
Weinreb, O., Bar-Am, O., Amit, T.,
Chillag-Talmor, O., and Youdim, M.
B. (2004). Neuroprotection via pro-
survival protein kinase C isoforms
associated with Bcl-2 family mem-
bers. FASEB J. 18, 1471–1473.
Wu, A., Ying, Z., and Gomez-Pinilla,
F. (2004). Dietary omega-3 fatty
acidsnormalizeBDNFlevels,reduce
oxidative damage, and counteract
learning disability after traumatic
brain injury in rats. J. Neurotrauma
21, 1457–1467.
Wu, D. C., Jackson-Lewis, V., Vila, M.,
Tieu, K., Teismann, P., Vadseth,
C., Choi, D. K., Ischiropoulos,
H., and Przedborski, S. (2002).
Blockade of microglial activation is
neuroprotective in the 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine
mouse model of Parkinson disease.
J. Neurosci. 22, 1763–1771.
Wullner, U., Loschmann, P. A., Schulz,
J. B., Schmid, A., Dringen, R.,
Eblen, F., Turski, L., and Klock-
gether,T.(1996).Glutathionedeple-
tion potentiates MPTP and MPP+
toxicity in nigral dopaminergic neu-
rones. Neuroreport 7, 921–923.
Wurtman, R. J., Ulus, I. H., Cansev, M.,
Watkins, C. J., Wang, L., and Mar-
zloff, G. (2006). Synaptic proteins
and phospholipids are increased
in gerbil brain by administering
uridine plus docosahexaenoic
acid orally. Brain Res. 1088,
83–92.
Xu, C. J., Klunk, W. E., Kanfer, J. N.,
Xiong, Q., Miller, G., and Pette-
grew,J.W.(1996).Phosphocreatine-
dependent glutamate uptake by
synapticvesicles.Acomparisonwith
atp-dependent glutamate uptake. J.
Biol. Chem. 271, 13435–13440.
Xu,K.,Xu,Y.,Brown-Jermyn,D.,Chen,
J. F.,Ascherio,A., Dluzen, D. E., and
Schwarzschild, M. A. (2006). Estro-
gen prevents neuroprotection by
caffeine in the mouse 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine
model of Parkinson’s disease. J.
Neurosci. 26, 535–541.
Xu, K., Xu, Y. H., Chen, J. F., and
Schwarzschild, M. A. (2002). Caf-
feine’s neuroprotection against
1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine toxicity shows
no tolerance to chronic caffeine
administration in mice. Neurosci.
Lett. 322, 13–16.
Xu, K., Xu, Y. H., Chen, J. F., and
Schwarzschild,M.A.(2010).Neuro-
protection by caffeine: time course
and role of its metabolites in the
MPTP model of Parkinson’s disease.
Neuroscience 167, 475–481.
Xu, Q., Kanthasamy, A. G., and Reddy,
M. B. (2008). Neuroprotective effect
of the natural iron chelator, phytic
acid in a cell culture model of
Parkinson’s disease. Toxicology 245,
101–108.
Xu, Q., Kanthasamy, A. G., and Reddy,
M. B. (2011). Phytic acid protects
against 6-hydroxydopamine-
induced dopaminergic neuron
apoptosis in normal and iron excess
conditions in a cell culture model.
Parkinsons Dis. 2011, 431068.
Yang, L., Calingasan, N. Y., Wille, E. J.,
Cormier, K., Smith, K., Ferrante, R.
J., and Beal, M. F. (2009). Combi-
nation therapy with coenzyme Q10
and creatine produces additive neu-
r o p r o t e c t i v ee f f e c t si nm o d e l so f
Parkinson’s and Huntington’s dis-
eases.J.Neurochem.109,1427–1439.
Frontiers in Neurology | Neuropharmacology November 2011 | Volume 2 | Article 68 | 18Seidl and Potashkin Neuroprotection in Parkinson’s disease
Yang, L., Sugama, S., Chirichigno, J. W.,
Gregorio, J., Lorenzl, S., Shin, D. H.,
Browne,S.E.,Shimizu,Y.,Joh,T.H.,
Beal, M. F., and Albers, D. S. (2003).
Minocycline enhances MPTP tox-
icity to dopaminergic neurons. J.
Neurosci. Res. 74, 278–285.
Yavin, E., Brand, A., and Green, P.
(2002).Docosahexaenoicacidabun-
dance in the brain: a biodevice to
combat oxidative stress. Nutr. Neu-
rosci. 5, 149–157.
Yogev-Falach, M., Amit, T., Bar-Am,
O., and Youdim, M. B. (2003).
The importance of propargylamine
moiety in the anti-Parkinson drug
rasagiline and its derivatives in
MAPK-dependent amyloid precur-
sor protein processing. FASEB J. 17,
2325–2327.
Yokota, T., Igarashi, K., Uchihara, T.,
Jishage, K., Tomita, H., Inaba,A., Li,
Y., Arita, M., Suzuki, H., Mizusawa,
H., and Arai, H. (2001). Delayed-
onset ataxia in mice lacking alpha-
tocopherol transfer protein: model
forneuronaldegenerationcausedby
chronic oxidative stress. Proc. Natl.
Acad. Sci. U.S.A. 98, 15185–15190.
Yong, V. W., Perry, T. L., and Kris-
man, A. A. (1986). Depletion
of glutathione in brainstem of
mice caused by N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine is pre-
vented by antioxidant pretreatment.
Neurosci. Lett. 63, 56–60.
Youdim, M. B., Amit, T., Falach-
Yogev, M., Bar Am, O., Maruyama,
W., and Naoi, M. (2003). The
essentiality of Bcl-2, PKC and
proteasome-ubiquitin complex acti-
vations in the neuroprotective-
antiapoptotic action of the anti-
Parkinsondrug,rasagiline.Biochem.
Pharmacol. 66, 1635–1641.
Youdim, M. B., Gross, A., and Fin-
berg, J. P. (2001a). Rasagiline
[N-propargyl-1R(+)-aminoindan],
a selective and potent inhibitor
of mitochondrial monoamine
oxidase B. Br. J. Pharmacol. 132,
500–506.
Youdim, M. B., Wadia, A., Tatton, W.,
and Weinstock, M. (2001b). The
anti-Parkinson drug rasagiline and
its cholinesterase inhibitor deriva-
tives exert neuroprotection unre-
lated to MAO inhibition in cell cul-
tureandinvivo.Ann.N.Y.Acad.Sci.
939, 450–458.
Youdim, M. B., and Weinstock, M.
(2001). Molecular basis of neuro-
protectiveactivitiesof rasagilineand
the anti-Alzheimer drug TV3326
[(N-propargyl-(3R)aminoindan-5-
YL)-ethyl methyl carbamate]. Cell.
Mol. Neurobiol. 21, 555–573.
Yrjanheikki, J., Keinanen, R., Pel-
likka, M., Hokfelt, T., and Koisti-
naho,J. (1998). Tetracyclines inhibit
microglial activation and are neuro-
protective in global brain ischemia.
Proc. Natl. Acad. Sci. U.S.A. 95,
15769–15774.
Yu, Z. F., Bruce-Keller, A. J., Goodman,
Y., and Mattson, M. P. (1998). Uric
acid protects neurons against exci-
totoxic and metabolic insults in cell
culture, and against focal ischemic
brain injury in vivo. J. Neurosci. Res.
53, 613–625.
Zhang, S. M., Hernan, M. A., Chen, H.,
Spiegelman, D., Willett, W. C., and
Ascherio, A. (2002). Intakes of vita-
mins E and C, carotenoids, vitamin
supplements,andPDrisk.Neurology
59, 1161–1169.
Zhao,C.,Ling,Z.,Newman,M.B.,Bha-
tia, A., and Carvey, P. M. (2007).
TNF-alpha knockout and minocy-
cline treatment attenuates blood-
brain barrier leakage in MPTP-
treated mice. Neurobiol. Dis. 26,
36–46.
Zhou, W., Bercury, K., Cummiskey, J.,
Luong,N.,Lebin,J.,and Freed,C. R.
(2011). Phenylbutyrate up-regulates
the DJ-1 protein and protects neu-
rons in cell culture and in animal
models of Parkinson disease. J. Biol.
Chem. 286, 14941–14951.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 12 September 2011; paper
pending published: 10 October 2011;
accepted: 21 October 2011; published
online: 21 November 2011.
Citation: Seidl SE and Potashkin JA
(2011) The promise of neuroprotective
agentsinParkinson’sdisease.Front.Neur.
2:68. doi: 10.3389/fneur.2011.00068
This article was submitted to Frontiers
in Neuropharmacology, a specialty of
Frontiers in Neurology.
Copyright © 2011 Seidl and Potashkin.
This is an open-access article subject
to a non-exclusive license between the
authors and Frontiers Media SA, which
permits use, distribution and reproduc-
tioninotherforums,providedtheoriginal
authorsandsourcearecreditedandother
Frontiers conditions are complied with.
www.frontiersin.org November 2011 | Volume 2 | Article 68 | 19